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CHAPTER 1  
INTRODUCTION 
 
This thesis describes the motivation for, development of, and evaluation of the 
chemotherapy plan abstraction method (CPAM), and its use for cohort plan analysis. This 
introduction defines the concepts related to the generic and clinical tasks of planning and 
plan abstraction, and their importance in clinical practice and research. 
1.1. Plan abstraction 
Plan abstraction is an important generic and clinical reasoning task. Table 1.1 
defines the concepts related to planning and plan abstraction. An intended plan is a 
sequence of future actions specified by an actor to achieve a goal. Planning is the task of 
specifying a plan. When a plan is executed, the sequence of pre-specified actions is 
carried out. Some of those actions will have associated artifacts (e.g., execution 
timestamp and serial ordinal number) that can be reviewed by an outside observer. The 
executed plan, therefore, can include modifications due to execution time changes in the 
state of the plan components. Plan abstraction is the task of inferring the existence of a 
plan from the pattern of observed events(1; 2). Plan recognition, on the other hand, is the 
task of establishing a correspondence between a sequence of observed events and a 
known set of established plans(1). Cohort plan analysis is the task of conducting a 
collective analysis of plans executed by a cohort of actors. 
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Table 1.1. Definition of concepts related to plan abstraction. 
Definitions include the generic (domain non-specific) context, general clinical 
context, and chemotherapy context. 
Term / 
Concept 
Generic Task Clinical Task Chemotherapy Task 
Intended 
plan 
A sequence of 
actions specified by 
an actor to achieve a 
goal. 
A sequence of diagnostic 
or therapeutic events 
specified by a clinician 
with the goal of 
improving a patient’s 
duration or quality of life. 
A sequence of 
chemotherapy medication 
events specified by an 
oncologist with the goal of 
treating a specific cancer 
and improving the 
patient’s duration or 
quality of life. 
Executed 
plan 
A completed plan 
with observable 
artifacts in terms of a 
sequence of events 
corresponding to the 
plan implementation. 
A completed diagnostic 
or therapeutic plan with a 
sequence of recorded 
clinical events 
corresponding to the 
plan. 
A completed 
chemotherapy plan with a 
sequence of recorded 
chemotherapy medication 
events corresponding to 
the plan. 
Planning Task of specifying a 
plan. 
Clinical task of 
specifying a clinical plan. 
Clinical task of specifying 
a chemotherapy plan. 
Plan 
abstraction 
Task of inferring 
executed plans from 
an observed 
sequence of past 
events. 
Clinical task of inferring 
a clinical plan from a 
sequence of past 
diagnostic or therapeutic 
events. 
Clinical task of inferring a 
chemotherapy plan from 
an observed sequence of 
the past chemotherapy 
medication events. 
Plan 
recognition 
Task of establishing 
a correspondence 
between an observed 
sequence of past 
events and a known 
set of established 
plans. 
Clinical task of matching 
an observed set of 
clinical events to a 
known set of clinical 
plans. 
Clinical task of matching 
an observed set of 
chemotherapy medication 
events to a known set of 
chemotherapy plans. 
Plan 
selection 
Task of selecting 
from among a set of 
plans that can all 
achieve the same 
goal. 
Clinical task of selecting 
from among an 
established set of 
diagnostic or treatment 
plans for a given disease. 
Task of selecting from 
among an established set 
of chemotherapy protocols 
to treat a given type and 
stage of cancer. 
Cohort plan 
analysis 
An analysis of the 
executed plans of a 
cohort of actors 
A clinical analysis of the 
executed diagnostic and 
therapeutic plans of a 
cohort of patients. 
A clinical analysis of the 
executed chemotherapy 
plans of a cohort of cancer 
patients. 
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1.2. Plan abstraction in medicine 
An intended clinical plan is a sequence of future diagnostic or therapeutic events 
specified by a provider with the goal of improving the patient’s duration or quality of life. 
Clinical planning is the task of specifying a clinical plan. Many clinical plans are highly 
specific for a particular disease, and are established as a standard of care through clinical 
research. A clinician prescribes an appropriate clinical plan for a given disease condition 
through a process of plan selection, while balancing between likely relative efficacy, 
side-effects and cost. An executed clinical plan consists of the completed sequence of 
clinical events corresponding to the intended plan. The actual events, though, can deviate 
from the intended course of the plan (e.g., due to inability of the patient to tolerate the 
side-effects). The task of clinical plan abstraction involves inferring the clinical plan 
from actual clinical events. Clinical plan recognition is the task of establishing a 
correspondence between the observed sequence of clinical events and the set of known 
clinical plans established as standard of care. 
Clinical care follows a cyclical process of diagnosis, treatment plan selection, 
treatment plan management, and response assessment tasks (Figure 1.1). Diagnosis is the 
task of ascertaining the disease condition while response assessment is the task of 
evaluating how the disease condition changes in the context of treatment. Treatment plan 
management is the task of scheduling, customizing, and iteratively refining the intended 
plan events based on the outcome of the response assessment task. A treatment summary 
is a concise statement summarizing the clinical events associated with an executed 
treatment plan. Plan abstraction is the essential task of deriving the treatment summary 
 from observed clinical events
both the treatment selection
 
Figure 1.1. Disease management and plan abstraction tasks
Disease management is a cyclical process, consisting of 
selection, treatment plan management and treatment response assessment tasks. 
The treatment history is reviewed in terms of treatment plans that correspond to the 
respective treatment protocols, and plan abstraction task produces treatment plans 
from the treatment events stored in 
the treatment selection task
treatment is reviewed and managed with respect to the disease response and is 
either continued or
 
Clinical cohort plan analysis is the task of 
for a cohort of patients. Such 
adherence to standard of care
effectiveness of multiple treatment plans, and 
4 
. The treatment summary provides important feedback 
 and the treatment management tasks (figure 1.1). 
. 
diagnosis, 
EMR. The treatment history is reviewed during 
 and treatment plan management task
 revised. 
evaluating a set of executed clinical plans 
cohort level analysis can address questions related to patient 
 plans, physician practice patterns, the 
the comparative cost of multiple plans. 
for 
 
 
treatment 
. The current 
comparative 
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1.3. Chemotherapy plan abstraction 
The chemotherapy version of the concepts listed in table 1.1 can be defined in a 
similar fashion as those for the clinical tasks, except that in case of chemotherapy all 
events represent the chemotherapy drug events.  
Chemotherapy plans are a class of protocol-based treatments consisting of 
specialized drugs to kill cancer cells while minimizing toxicity to the patient. Individual 
patients show varying degrees of tolerance to chemotherapy drug treatments. As such, it 
is common for the executed chemotherapy plan to have minor or major deviations from 
the intended plan to account for patient toxicity. Chemotherapy protocols are highly 
complex treatment plans specific to a particular cancer type, and are established as 
standard of care through rigorous clinical research. Some chemotherapy plans span many 
months or even years, and can consist of hundreds of distinct drug events. A given plan 
can consist of multiple drugs and a given drug may be part of multiple plans.  
Figure 1.2 shows several examples of simple and complex intended (panel A) and 
executed (panel B) chemotherapy plans and their respective treatment summaries (panel 
C). Intended chemotherapy plans (Figure 1.2-A) are specified as a set of medication 
events that repeat at a given frequency and number of cycles. For example, plan 1 is a 
simple chemotherapy plan consisting of a single drug paclitaxel (‘P’) that is repeated 
every twenty-one days for four cycles. Plan 3 on the other hand is a more complex plan 
that consists of two drugs repeated in multiple nested cycles. In plan 3, cisplatin (‘C’) is 
given on day 1 only while etoposide (‘E’) is given daily for three days starting on day1. 
The whole set is repeated every twenty-one days for six cycles. 
 Figure 1.2. Plan representations
Panel A shows 
marked in the box
repeats (e.g., 
consisting of only one drug (
another simple plan that repeats every three weeks, but it cons
(bevacizumab
consists of drugs 
times daily starting day 1; the whole set is then repeated 
the first day, Etoposide is then repeated 
shows executed plans
Actual dates and day#s are stated for individual medication events.
representation of 
abstracted plans shows the start
periodicity disc
 
Panel B of figure 1.2 shows 
that can result from execution of these plans
versions of these plans, which forms 
to inferring the constituent drugs, the abstracted version also shows the start date, end 
date, number of cycles, 
6 
. 
intended plans. The looping arrow indicates ‘repetition’ of the drug 
, q gives the frequency of repetition, and x gives the number of 
q21x4 indicates repeat every 21 days 4 times).  Plan 1
paclitaxel – ‘P’) repeating every three weeks. Plan 2 is 
ists of multiple drugs 
 – ‘B’, carboplatin – ‘C’ and paclitaxel – ‘P’). Plan 3 is complex 
cisplatin – ‘C’ given on day 1 and etoposide 
; that are given together on 
six times every twenty-one days. 
 corresponding to the intended plans shown in 
abstracted plans as inferred from the events in panel B. 
-date, end-date, number of cycles and average 
erned from the observed events.  
the respective examples of the actual sequence of events 
. Panel C shows the corresponding 
a treatment summary for a given patient
and average periodicity (rate of repetition) for the respective 
 
 is a simple plan 
and 
– ‘E’ repeated 3 
Panel B 
panel A. 
 Panel C gives a 
The list of 
abstracted 
. In addition 
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plans. The actual rate of repeat (averaged over all the cycles) for each of these plans is 
longer than that suggested by the respective plans, which demonstrates that the intended 
plan is not always executed as designed in order to account for patient response to the 
treatment. 
Cancer care follows the same cyclical process of diagnosis, chemotherapy plan 
selection, chemotherapy plan management and response assessment (in terms of tumor 
size and patient tolerance) tasks, as shown in figure 1.1. During the plan selection task, 
the oncologist uses the treatment summary as the record of therapies the patient has 
previously completed to inform selection of the next treatment. During the chemotherapy 
plan management task, the oncologist uses the summary of the current executed plan to 
recall any deviations from the intended plan due to toxicity.  
Organizations like ASCO recommend using cancer treatment summaries(3) to 
record the details of an executed cancer treatment. ASCO’s chemotherapy treatment plan 
and summary templates were developed to help improve documentation and coordination 
of cancer treatment and survivorship care. They are intended to facilitate provider-to-
provider and provider-to-patient communication. The completed treatment summaries are 
recorded in the patient chart and can be distributed to the patient and to their providers. 
Importantly, the treatment plan and summary are not intended to replace detailed chart 
documentation, including complete patient histories or chemotherapy flow sheets. 
However, manual generation of a chemotherapy treatment summary can be a very 
time consuming task for clinicians in practice. In addition to cognitive stress of 
discerning patterns pertaining to complex plans there are challenges associated with the 
extraction of medication events from the medical records and technical intricacies 
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accompanying clinical data sources. Chapter 2 further elaborates on the challenges of 
extracting medication events and intricacies of accessing clinical data sources. 
 
Table 1.2. Questions that can be addressed for cohort analysis. 
Operational, quality, and research questions addressed when plan history information 
is available for cohort analysis. Questions may be across or within plans, across or 
within disease and with disease feature restrictions.  Listed are several questions (Q) 
across these dimensions and their clinical utility (U). 
Available Data 
Sources Cohort Analysis Across Plans Cohort Analysis Within a Plan 
Treatment 
History alone 
Q: What are the most frequently used 
plans across all cancer diagnosis? 
U: Resource utilization 
U: Cost analysis 
U: Prioritize CPOE order set 
implementation 
U: Pharmacy supply management 
Q: What is the variance in sequencing, 
total number of cycles, and cycle 
frequency for a given plan across cancer 
diagnosis? 
U: Estimate of variance in plan utilization 
across cancer diagnoses 
Treatment 
History plus 
Cancer 
Diagnosis 
Q: What are the most frequent plans for 
a given cancer diagnosis? 
Q: Which plans are most often used first, 
second, or third in treatment 
sequencing for a given cancer 
diagnosis? 
U: Analysis of variance in provider 
practice patterns within and across 
institutions 
Q: What is the variance in sequencing, 
total number of cycles, and cycle 
frequency for a given plan for a single 
cancer diagnosis? 
U: Estimate of patient toxicity to plan 
U: Estimate of average disease progression 
on plan 
Treatment 
History plus 
Cancer 
Diagnosis, 
Cancer Stage, 
Tumor 
Biomarkers, and 
Patient Survival 
Q: What are the most frequent plans for 
a given cancer diagnosis, stage, and 
set of biomarkers? 
U: Analysis of variance in provider 
practice patterns within and across 
institutions 
U: Analysis of provider compliance with 
standard guidelines 
Q: What is the comparative efficacy of 
plans for a given cancer diagnosis, 
cancer stage and set of tumor 
biomarkers?  
U: Comparative effectiveness research 
on large populations 
Q: What is the variance in sequencing, 
total number of cycles, and cycle 
frequency for a given plan for a single 
cancer diagnosis, stage and biomarker? 
U: Estimate of patient toxicity to plan 
U: Estimate of average disease progression 
on plan 
Q: What is the comparative efficacy of a 
given plans for a given cancer diagnosis, 
cancer stage and set of tumor 
biomarkers? 
U: Predictive and prognostic biomarker 
discovery for a given plan.  
 
When detailed chemotherapy plan histories are available for a large cohort of 
patients, many questions can be addressed related to quality, efficacy, and cost of care 
(Table 1.2). For example, when chemotherapy plan history alone is available, a cohort 
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level analysis across all plans can reveal the frequency of treatment plans at a given 
institution. A computerized provider order entry (CPOE) implementation team could use 
this information to help prioritize creating order set templates at their facility. Several 
more questions can be addressed when the cancer diagnosis information is added. For 
example, what are some of the most frequently administered chemotherapy protocols for 
a given cancer diagnosis?   This can give information on provider practice patterns within 
and across institutions, including insight into provider awareness of existing knowledge 
and resource utilization(4).  Likewise, a within plan analysis of a given disease can 
include an evaluation of the variance in sequencing, total number of cycles, and cycle 
frequency for a given plan. In the case of a plan for a metastatic cancer for instance, the 
median duration of treatment could correlate with the median time to disease progression 
in that patient population. 
Such cohort level analyses, however, are currently very time-consuming to perform 
since researchers must manually recreate the treatment history from clinical documents 
stored in the EMR, as exemplified by the study conducted by Zafar et al.(5) 
1.4. Chemotherapy plan abstraction as a temporal abstraction task 
Chemotherapy plans involve one or more drugs repeated over a number of cycles, 
for a specified periodicity. Considering the discrete drug events as instances along the 
temporal dimension it is possible to apply temporal reasoning methods to solve the 
problem of chemotherapy plan abstraction. Identifying individual instances by 
corresponding drug-name and time-stamp can help establish temporal patterns among the 
sequence of events. Application of temporal logic enables extraction of such attributes as 
the periodicity and cycle length of plans inferred from the temporal patterns. Whereas 
10 
 
plan recognition needs to use an external knowledge base of standard plans as a reference 
to recognize the plan from the executed sequence of events, a plan abstraction method 
could be created that relies solely on the content of data to infer plans and derive the 
related attributes. 
I therefore hypothesize that it is possible to create a chemotherapy plan abstraction 
method that takes as input distinct chemotherapy drug events and accurately generate as 
output a temporal sequence of chemotherapy treatment summaries in terms of abstracted 
plans. 
1.5. Overview of the thesis document 
The following six chapters describe the development of the Chemotherapy Plan 
Abstraction Method (CPAM) and its application to cohort plan analysis.  Chapter 2 
describes the challenges of performing the chemotherapy plan abstraction and cohort plan 
analysis tasks in the clinical and research settings. Chapter 3 reviews the temporal 
reasoning literature related to the computational task of plan abstraction. This chapter 
includes a discussion of the dimensions of the plan recognition and plan abstraction tasks, 
prior work related to these dimensions, and their limitations. 
Chapter 4 describes the CPAM, a data-driven temporal reasoning method that takes 
as input chemotherapy medication events and generates as output a sequence of abstract 
chemotherapy plans for patients in multiple cancer domains. This chapter describes the 
details of the data extraction method, pre-processing method, and plan abstraction 
method. Chapter 5 describes the evaluation methodology and results, including an 
evaluation of the performance of the CPAM at a patient level, and an evaluation of the 
clinical utility of the abstracted plans for cohort plan analysis.  
11 
 
Chapter 6 discusses the contributions and limitations of the CPAM in the domains of 
informatics and medicine. Chapter 7 discusses possible future work including iterative 
improvements to the CPAM and its potential applications for patient care and clinical 
research. 
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CHAPTER 2   
CHALLENGES OF CLINICAL PLAN ABSTRACTION 
 
As recommended by ASCO(3), oncologists will often create a treatment summary 
for each course of treatment as an unstructured text document. These treatment 
summaries have several limitations. First, each individual summary provides an overview 
of a specific set of treatment events, but lacks an overall view of the patient’s entire 
treatment history. Second, they lack structure to enable use by downstream systems for 
clinical decision support or cohort analysis. Third, they are time consuming to produce 
since the only way to obtain the executed plan summary is by abstracting the plans from 
the chronology of past medication events. Finally, there are limitations with respect to the 
accuracy and truthfulness of past medication events that can be derived from the EMR. 
This chapter discusses the challenges associated with accessing the medication events 
from the EMR system for the purpose of chemotherapy plan abstraction. 
2.1. Challenges related to extraction of medication events from the EMR 
An executed clinical plan consists of a sequence of recorded clinical events that 
correspond to an intended clinical plan (table 1.1, figure 1.2). The EMR records these 
clinical events in many different and complementary ways. Some event records 
correspond more closely to the intended event (e.g., clinical order record) than to the 
executed event (e.g., nursing medication administration record). Some events are 
recorded in highly structured ways while others are recorded in free text, resulting in a 
variable accuracy in extracting these events. The following subsections describe the 
challenges related to medication event data extraction from the EMR systems. 
13 
 
2.1.1. Clinical information artifacts for medication events 
Treatment information is recorded in several types of clinical records and in various 
formats that have varying degrees of accessibility to automated systems. Providers often 
use multiple clinical data sources to extract the treatment summary. Each data source has 
advantages and disadvantages for manual or automated plan abstraction. 
2.1.1.1. Truthfulness of event and data accuracy. 
Plan abstraction requires accurate medication event data. Two levels of accuracy are 
apparent, event truthfulness and data accuracy. Event truthfulness refers to the confidence 
associated with the event having actually occurred. Data accuracy refers to the 
completeness and faithfulness with which event data is reproduced from a given data 
source. For a given EMR implementation, and the corresponding clinical data sources, 
there is an implicit decision process of optimization between event truthfulness and data 
accuracy. 
2.1.1.2. Clinical data sources 
The data sources considered for the purpose of chemotherapy plan abstraction 
method are clinical notes, provider orders, provider order sets, pharmacy dispensing 
records, and nursing medication administration records.  Table 2.1 presents a categorical 
summary of each clinical data source across the following dimensions: temporal context, 
degree of structure, storage format, data completeness, and medication information. 
These dimensions are analyzed with respect to truthfulness and data accuracy. 
The temporal Context refers to the temporal context of medication events recorded 
in each type of document including reference to the past, current or intended medication 
14 
 
events or plans. The information pertaining to the future events only conveys an 
intention, limiting the truthfulness of the event having actually occurred. 
The degree of structure refers to whether the data elements of medication events are 
in structured or free-text format. The degree of structure affects the data accuracy of the 
events. 
The storage format refers to the medium of data storage. Data stored on paper can be 
accessed manually, but only by a single user at a time. Data stored in digital media can be 
accessed by multiple simultaneous users as well as by automated or programmable 
systems. Text files stored as image files are more difficult for automated systems to 
process than text stored in an ASCII format. The storage format affects the data accuracy 
of the events. 
Data completeness refers to the extent of availability of data pertaining to different 
types of medication events, e.g., events pertaining to the medications taken at home, or 
taken outside a given institution. This data informs the degree of truthfulness of events. 
Medication information refers to the data elements of the individual medication 
events, e.g., the drug name, drug code, dosage, route, and schedule (time-stamp). This 
dimension along with degree of structure influences the data accuracy of the events. 
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Table 2.1. Categorical summary of clinical data sources. 
Summary of clinical data sources by various dimensions affecting the truthfulness 
and data accuracy. [V ≡ Implementation level at Vanderbilt University Medical 
Center; * ≡ Naming / Coding convention may be local to the institution.] 
D
im
e
n
si
o
n
 
Attribute 
Clinic 
Notes 
Provider 
Orders 
Provider 
Order Sets 
Pharmacy 
Dispensing 
Records 
Nursing Medication 
Administration 
Record 
T
em
p
o
ra
l 
C
o
n
te
x
t 
Current 
Medication 
Events 
+ + + + + 
Past 
Medication 
Events 
+ - - - - 
Future 
Medication 
events 
+ - - - - 
Current plan + - + - - 
Past plan + - - - - 
Future plan + - - - - 
D
eg
re
e 
o
f 
st
ru
ct
u
re
 Free text + + + - + 
Semi-
structured 
+/- + 
(V 95%) 
+  
(V 95%) 
- +  
(V 95%) 
Highly 
structured 
- + 
(V 5%) 
+ 
(V 5%) 
+ 
(V 100%) 
+ 
(V 5%) 
S
to
ra
g
e 
fo
rm
at
s 
Paper + + - - + 
Scanned Image 
Files 
+ (V) +  
(V 95%) 
+  
(V 95%) 
- + 
Digital + (V) + 
(V 5%) 
+ 
(V 5%) 
+ (V) + 
(V 100%) 
D
at
a 
C
o
m
p
le
te
n
es
s 
Administered 
Medications 
+ + 
(V 5%) 
+ 
(V 5%) 
+ 
(V 100%) 
+ 
(V 100%) 
Medications 
taken at home 
+ + 
(V 45%) 
- - N/A 
Within 
Institution 
record 
+ + + + + 
Outside 
Institution 
record 
+ - - - - 
M
ed
ic
at
io
n
 I
n
fo
rm
at
io
n
 Plan Name +* - +* - +/- 
Drug Name +* +* +* + + 
Drug Code - +* +* + +* 
Dosage  
(e.g., mg/m
2
) 
- + + + + 
Dose Amount 
(e.g., mg) 
+ + + + + 
Route (e.g., iv) + + + + + 
Schedule + + + + + 
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The following paragraphs describe the data sources in greater detail with respect to 
these dimensions. Table 2.2 lists the relative advantages and disadvantages of the data 
sources. 
Clinical notes: For every patient encounter, the provider creates a clinical note to 
record the details about the patient history, physical exam, test results, treatment plan and 
response assessment. The information can include a summary of the past, current, and 
intended medication events and treatment plans. When cancer treatments consist of 
multiple cycles that span many months, the providers often record information regarding 
the current treatment plan in their clinic notes and typically refer to the most recent 
clinical note to remind them of the state of the current plan.  Even with these reminders, 
the providers often lose track of the current cycle number and must use other sources to 
reconstruct the most recent history. 
Clinical notes are typically recorded in free text format. In the absence of an EMR 
implementation, the notes are handwritten on paper, and any subsequent information 
extraction is only feasible through manual review. EMR implementation allows direct 
entry of notes into the system that can then be accessed by programmable processes. The 
notes prior to the EMR implementation can be scanned and brought into the EMR system 
as image files with limited ability for data extraction.  The information contained in 
notes, however, is largely unstructured. To obtain any meaningful information, 
moderately sophisticated natural language processing (NLP) methods are required. The 
accuracy of information extracted from such methods however is limited and highly 
variable(6)
, 
(7)
,
(8).  
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Table 2.2. Advantages and disadvantages of various clinical data sources. 
[BCMA= Bar code medication administration.]  
Data 
Source 
Advantages Disadvantages 
C
li
n
ic
al
 N
o
te
s 
• Text documents ubiquitously available. 
• Can provide data about other events 
temporally correlated to medication 
events 
• Requires NLP to extract medication 
events and plans with variable accuracy, 
and temporal ambiguity(6)
,
(7)
,
(8)  
• Mention of medication indicates 
intention that may not result in 
corresponding administration event.  
P
ro
v
id
er
 O
rd
er
s 
• Computerized provider order entry 
(CPOE) systems contain well structured 
medication event data 
• CPOE systems provide electronically 
readable data that can be used by 
automated and programmable systems 
• Can provide data about other treatment 
events temporally correlated to 
medication events 
• Medications administered may differ 
from the order in dose or schedule, or 
may not actually be administered 
• The level of uncertainty of corresponding 
administration event is considerably 
smaller than that of clinical notes 
P
ro
v
id
er
 O
rd
er
 
S
et
s 
• Contain an order set name that may 
correspond to an abstract plan name 
• When unchanged, the order set name is 
consistently used across providers within 
an institution 
• Group medication events that are part of 
a plan 
• Order set name is institution specific and 
not standardized 
• Order sets may be used as a starting point 
template for a completely different plan 
• The level of uncertainty of corresponding 
to the plan is smaller than that of clinical 
notes 
P
h
ar
m
ac
y
 
D
is
p
en
si
n
g
 
R
ec
o
rd
s 
• Most hospitals have electronic pharmacy 
systems 
• Contain well structured medication event 
data 
• Provide electronically readable data that 
can be used by automated and 
programmable systems 
• Medication administered may differ from 
the pharmacy order in dose or schedule 
or may not actually be administered.  
• The level of uncertainty of corresponding 
administration event is smaller than that 
of provider orders or order-sets 
N
u
rs
e 
M
ed
ic
at
io
n
 
A
d
m
in
is
tr
at
io
n
 
R
ec
o
rd
 
• Most accurate document of what patient 
actually received (drug, dose, schedule, 
including time-stamp)  
• BCMA contains structured data about the 
administered drugs including time-stamp 
of administration, coded drug name, 
dose, units, route, schedule and 
frequency 
• Free text requires NLP to extract 
medication events 
• BCMA systems have limited use in most 
outpatient chemotherapy infusion centers 
 
Provider orders: Provider orders contain information about the provider’s intended 
plan of treatment and include orders for medications, procedures and lab tests. In many 
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systems orders are documented on paper, which are stored as such or scanned into a 
digital storage as image files. In either case, to obtain medication information, the 
accessibility to these documents is limited to manual processing.  
CPOE systems allow providers to enter structured orders that are recorded 
electronically. If CPOE is implemented the order information can easily be retrieved 
using standard tools. Unlike clinical notes no NLP is required and the data available is 
highly accurate, as to the ordering event of the medication. The medication event data 
obtained from provider orders is only the intention to administer the medication 
treatment. Some proportion of orders may be cancelled before being fulfilled by the 
pharmacy. Cancellations occur for many reasons including, lack of available drug, or a 
change in the patient state or treatment plan. These cancellations can affect the accuracy 
of medication event data obtained from provider orders and special processing is thus 
required. Clinical orders, however, have a higher degree of certainty with respect to 
current medication event than clinical notes, but not as certain as medication 
administration event records. Finally, provider orders are limited to a single institution 
and do not contain information about the orders outside a given medical facility. 
Provider order-sets: Many implementations of CPOE allow for the creation of order 
sets, a collection of orders that are defined by a specific treatment protocol.  Order sets 
facilitate ordering a complete set of drugs in the protocol all at once, rather than creating 
multiple individual orders from memory. Medications ordered using order sets retain all 
of the properties of regular orders described above. However, for the purposes of the plan 
abstraction task, order sets make two main contributions: 1) grouping medications 
together that belong to a plan creates a partial knowledge base of plans, and 2) order sets 
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are often assigned an institution specific identifiers including unique names and numbers, 
and their utilization can thus be tracked. Many institutions with CPOE order sets for 
chemotherapy solve the chemotherapy plan abstraction problem by looking at the order 
set name (or number). This approach has some advantages and disadvantages.  
When order sets are used, the order set name provides a consistent naming 
convention within the institution for that plan.  For example, the breast cancer plan "Dose 
Dense Adriamycin and Cytoxan" is a common adjuvant breast cancer plan that is also 
called "Dose Dense AC" or "dd AC" when written in short hand in clinical notes.  As 
such, providers will have variable representations of plan names in clinical notes, but 
order sets provide a consistent representation within the institution.  The order set names 
and identifiers, however, do not follow any national standard such that they can be 
compared across institutions. Yet, order sets are a convenient way to acknowledge plans 
that have a high likelihood of being the same intended plan across providers in a single 
institution, and are a more reliable representation of plan names than clinical notes. 
While this is useful for commonly prescribed plans, most institutions do not have the 
resources to create order sets for every variation of every possible chemotherapy plan. 
One institution’s recent implementation of a chemotherapy CPOE system for impatient 
and outpatient treatment required creation of over one thousand chemotherapy sets(9). 
 Some plans are only used once every few years for rare diseases.  Other plans are simply 
slight modifications of a more commonly used plan, and as such providers simply use the 
more common plan as a starting point template and modify it to transform to an alternate 
plan. Modifications can include changes in medication dose, deletion or addition of a 
medication or a modification to the plan schedule. It is, therefore, difficult to rely on the 
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order set name as the definitive evidence that the plan elements were administered to the 
patient.  
Furthermore, order sets do not capture the temporal frequency of plans. While each 
cycle may be represented by a separate order set, the provider has to remember how 
frequently each cycle should be given.  This is not represented in an order set view of 
chemotherapy plans. Finally, while inpatient CPOE order sets are relatively common, 
outpatient chemotherapy order management systems are less common. Availability of 
this type of data is lacking in many institutions. 
Pharmacy dispensing records: The hospital pharmacy information system (PIS) 
stores information for every medication dispensed that is intended for administration on 
the medical facility premises. This includes inpatient medications and outpatient 
medications to be administered in infusion centers. The PIS documents the medication 
events that are the closest representation of the corresponding administration event, short 
of administration itself. Thus the event data obtained from pharmacy dispensing records 
is a good representation of the executed medication events. Furthermore, most hospital 
facilities have implemented PIS, however they only store information pertaining to the 
dispense events at a single institution. 
Medication events in PIS are highly structured and can be readily retrieved. The 
pharmacy dispensing records store information related to the drug name, drug-code, 
dispense time-stamp, frequency, quantity, and billing charge. Many systems use National 
Drug Codes (NDC) as well as other drug coding systems to represent the names of drugs.   
Like CPOE systems, PIS are transaction systems that facilitate pharmacy workflow 
and billing.  Orders are cancelled through negation of charges. Cancellation of a 
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chemotherapy medication is recorded as a negation of the exact amount of the billing 
charge, while those for other medications can be a partial charge negation. Conventions 
for such cancellations vary with implementations and business rules at different facilities. 
The accuracy of reconstructing medication events obtained from pharmacy dispensing 
records is very high as long as the cancellations are addressed appropriately. 
Nurse medication administration records: Nurses create a record of each 
medication administered during an inpatient hospitalization or an outpatient infusion 
center visit. The nurse medication administration record is the highest level of truth that 
the patient received a particular medication. Each medication administration event 
records the drug name, dosage, administration time-stamp, and quantity given. These 
records reflect only the medication administration events within the premises of a given 
facility. 
Nurse medication administration records, at many facilities, are a paper-based or are 
documented in free text digital formats. Obtaining medication event information from 
these records involves manual or, if stored electronically, NLP processing. Some 
institutions have implemented bar-coded medication administration (BCMA) systems or 
structured nursing documentation systems. The medication administration event 
information in such cases is available in structured and complete format. This includes a 
structured coded drug identifier that uses a terminology similar to pharmacy systems.  
However, BCMA is rarely implemented at outpatient infusion centers where most of the 
chemotherapy drugs are administered.  
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2.1.1.3. Advantages and disadvantages of sources for chemotherapy events 
There is an implicit decision process for optimization between truthfulness of 
chemotherapy medication event and corresponding data accuracy for the task of 
chemotherapy plan abstraction. A comparison between the provider’s clinical notes and 
nurse administration records can provide a good example for event accuracy. A 
chemotherapy drug event recorded in clinical notes is only an intention of such an event 
to occur, whereas the same event recorded in nurse administration records provides the 
conclusive proof of occurrence of the event. If both the records are in free text format, 
data accuracy for either of these sources is limited. If the same chemotherapy event, 
however, is recorded in the CPOE or in the pharmacy dispensing records the event data 
accuracy would be very high. 
The BCMA records, if implemented and available, would provide the most accurate 
account of medication administration event in terms of event truthfulness and data 
accuracy. Given a choice between the CPOE and the pharmacy dispensing records, the 
later would provide a more accurate picture of chemotherapy drug events by virtue of 
being closer in time to the corresponding administration event. Also, relative to a given 
administration event, the corresponding provider orders in the CPOE system have a wider 
time-precedence as compared to the corresponding drug dispensing event. Moreover, 
electronic implementation of the pharmacy dispensing records has wider penetrance 
compared to CPOE implementations or provider order-set implementations. In an ideal 
scenario all of these sources could be used together and triangulated to provide a 
statistical certainty as to the degree of confidence in the occurrence of a medication 
event. 
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2.2. Challenges related to extracting chemotherapy plan history 
The executed chemotherapy plans are not recorded in structured abstracted version 
(figure 1.2C). The abstract versions of the plans therefore must be derived from the 
distinct medication events. Any task or process that derives the chemotherapy plans from 
the distinct medication events must be able to deduce the plan attributes for individual 
plans.  
An abstract representation of chemotherapy plan provides such attributes as the 
constituent drugs, number of elapsed cycles, average periodicity, the start date, and the 
end date. A chemotherapy plan history is a listing of executed plans (figure 1.2C) that are 
abstracted from the chronology of executed medication events (figure 1.2 B).  
A chemotherapy plan history is the treatment summary that an oncologist would refer to 
during the plan selection task (figure 1.1). The treatment summary not only contains the 
details of the actual plans administered, it also implicitly conveys the knowledge of the 
intended plans. It informs the oncologist regarding the sequence of the plans and the 
number of elapsed cycles of the past and current plan.  
Oncologists usually record such information as the current plan and the cycle 
number in clinical notes, to refer back to it during the subsequent encounter. The 
sequence of treatments is also recorded in summary sections of documents. Such 
documentation practices can be prone to transcription error and are often difficult to find 
in the sea of clinical records. Another approach is to reconstruct the treatment history by 
reviewing the history of distinct chemotherapy administration events, and creating an 
abstract conceptualization of the chemotherapy plans from the details and chronology of 
those events. Current interfaces, however, provide only simple formatting with basic 
 segregation of the event data. An example of one such interface is a chemotherapy flow 
sheet shown in figure 2.1. 
Figure 2.1. An example o
A visual aid interface provided for oncologists. For a given patient and date
it provides patient specifics, some lab
given to the patient along with the chronology of the 
 
Manually abstracting chemotherapy plans from distinct chemotherapy drug events is, 
at best, a sub-optimized process.
plan attributes, and calculating the 
during a patient encounter.
2.3. Challenges related to cohort plan analysis
Many prospective and retrospective cancer cohort studies take into account the 
patient’s treatment history as part of their analysis. Researchers commo
and record the patients’ treatment history through manual data collection 
chart reviews. At the individual patient level, they use similar techniques and data 
sources as the clinicians to perform the plan 
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f chemotherapy flows-sheet. 
-test data and lists the chemotherapy drugs 
administration events.
 Keeping mental record of the event order, inferring the 
average periodicity of the plan cycles is not feasible 
  
 
abstraction task. Such efforts are very costly, 
 
-range, 
 
nly reconstruct 
or retrospective 
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time consuming, and sub-optimal at best.  Due to the high cost of manual data extraction, 
these efforts tend to be restricted to small patient samples. 
2.3.1. Data sources beyond the EMR for cohort plan analysis 
The comparative effectiveness research (CER) between two or more chemotherapy 
plans is feasible only when detailed treatment history is available for a cohort of patients. 
CER is designed to inform health-care decisions by providing evidence on the 
effectiveness, benefits, and harms of different treatment options(10). There has recently 
been a big push by the US government to encourage CER(11).  However, CER usually 
requires large data sets that historically have only been available in large state and 
national cancer registries.  One such cancer registry is the SEER(12) database that 
contains patient demographic, date of diagnosis, cancer type, cancer stage, first line of 
treatment and vital status.  It is used to create national cancer incidence statistics(13). 
However, the treatment history in SEER and other cancer registries is limited to a listing 
of the drugs used in the first line of treatment and their start date. It does not contain any 
information regarding the doses of medications, their frequency, number of cycles, 
duration of treatment, or treatment response.  Nor does it contain any information on 
subsequent therapies, an important piece of information for CER beyond first line 
therapy. Furthermore these registries are incredibly expensive to maintain since they 
require manual data abstraction and data entry. 
Other researchers outside oncology have performed cohort plan analysis using 
administrative health data such as claims management system (CMS) databases(14). The 
CMS databases contain coded information on medication events that are billed to 
insurance as part of patient care. The medication billing records include a date of service 
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and a structured medication code. Yet others have performed analysis of large databases 
of pooled outpatient pharmacy records. 
2.3.2. Learning cancer systems for cohort analysis 
A learning cancer system (LCS) has recently been described to facilitate secondary 
use of EMR data for continuous CER with feedback to clinical decision support 
systems(15).  Given the heterogeneity of clinical information artifacts for treatment 
history and medication events, automated methods will be needed to facilitate 
chemotherapy plan abstraction to realize the promises of a LCS. Both clinicians and 
researchers thus have a need for a method that can create a rich set of treatment history 
attributes similar to that of ASCO’s treatment summary guideline(3). 
Cancer research is currently limited to learning from the clinical outcomes of only 
the 3% of the cancer patients who participate the clinical trials. The recent progress in 
molecular testing has increased the number of sub-types of cancer patients, thus shrinking 
the individual pools of the study participants. Some molecular variants could be too small 
to necessitate data aggregation over multiple institutions. Given this trend, it would be 
compelling to learn from the experience of all cancer patients (with their data 
anonymized), rather than a small proportion of them.  
2.4. Hypothesis 
To satisfy these requirements, I hypothesize that an automated plan abstraction 
method can accurately abstract medication plans from the temporal sequence of 
medication event records across multiple cancer domains. The following approach was 
used to test this hypothesis:  
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• Create a data-driven method for automated chemotherapy plan abstraction. 
• Test the performance of the method against a manually annotated gold standard 
set of chemotherapy plans. 
• Train and test the performance of the method on a data set limited to two cancer 
diagnoses. 
• Test the generalizability of the method performance on a separate data set that 
includes all cancer diagnoses except those in the previous step. 
• Demonstrate the utility of the method for cohort plan analysis using a large data 
set of medication events from a single cancer diagnoses at a single institution. 
• Perform an across plan analysis by identifying the most frequent plans for a given 
cancer diagnosis. 
• Perform a within plan analysis by exploring the variance in sequencing, total 
number of cycles, and cycle frequency for a given plan for a single cancer 
diagnosis. 
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CHAPTER 3  
TEMPORAL REASONING FOR PLAN ABSTRACTION 
 
Temporal reasoning is essential to successfully addressing problems of a time-
sensitive and dynamic world. Plan abstraction is a type of temporal reasoning task that 
takes as input time stamped events and produces as output a sequence of abstracted plans. 
Temporal representation and reasoning as an area of informatics research has been 
extensively reviewed(16–21). This chapter focuses on the dimensions of temporal 
abstraction methods as they relate to plan abstraction, prior work on temporal abstraction, 
and limitations of the prior approaches to perform the task of temporal abstraction. 
3.1. Dimensions of temporal abstraction methods 
Before discussing the abstraction methods and techniques, it is important to 
understand the dimensions involved in temporal abstraction (TA) methodologies. The 
dimensions of a typical TA method include input data, input knowledge, reasoning 
methods used to perform the temporal abstraction task, the abstracted output data, and the 
clinical domains of application. The following sections describe details of each of these 
dimensions. Table 3.1 lists three of the several methods discussed in the following 
sections, along with their dimensions. 
3.1.1. Input data 
TA creates higher level concepts from input of distinct event data represented as 
instances or intervals in time. In the medical domain higher level concepts are abstracted 
from clinical event data. Some examples of clinical event data are medications, clinical 
procedures, lab tests, and vital sign (temperature, blood pressure, pulse rate) 
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measurements. Clinical data event may itself be structured and contain data components. 
For example, in chemotherapy plan abstraction, the medication event has a drug-name 
and dose amount. 
 
Table 3.1: Summary of the temporal abstraction methods. 
Method Input Type 
Clinical 
Domain Output 
RESUME Time-stamped 
observational or 
treatment events 
Knowledge-
based 
AIDS, 
CGVHD 
Set of interval-based, 
context specific 
parameters at the same 
or higher level of 
abstraction, along with 
their respective values 
(based on 
KBTA) 
RASTA 
(distributed 
algorithm) 
Time-stamped 
event data and 
case-identifiers 
(patient-ID) 
Knowledge-
based Hypertension 
Structured datasets 
passed as XML to 
invoking application or 
stored in relational 
database 
CAPSUL  
Time-stamped 
event data 
pertaining to the 
procedures, 
treatments, and 
lab results 
Knowledge-
based 
Bone 
Marrow 
Transplant 
(BMT) 
Interval-based 
abstractions directly 
used by applications or 
displayed using 
visualization tool (e.g., 
KNAVE) 
 
The temporal granularity of input data defines the conceptual representation of the 
timestamp associated with the input event (e.g., a second, an hour, or a day). The 
RESUME system(22), for example, uses timestamps at specific predefined level of 
granularity. Complex temporal abstractions can be inferred from the input event data, but 
the set of granularity levels (and thus the implied temporal uncertainty) is limited to the 
finest granularity of the input data.  
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The complexity of TA task increases if multiple granularities are used for the input 
timestamps(19; 20); it is therefore desirable that the timestamp used for input events be 
uniform. Given the disparate and varying nature of data sources that provide the input 
event data (see chapter 2), it is often required to conform the input data to use consistent 
temporal granularity. Such procedures are covered by pre-processing steps. Conformation 
of the temporal granularity is but one of the pre-processing steps. Other pre-processing 
steps include filtering of input event data with-respect to desired type of events and fixing 
it with respect to the data content.  
3.1.2. Input knowledge 
The input knowledge used by TA methodology is typically known as a ‘knowledge 
base’. Some TA methods that use a ‘knowledge base’ as input can be applied across 
multiple domains. A knowledge base is useful as input in the creation of generalizable 
TA methods that are not domain- or problem-specific. In such implementations the 
methodology remains the same while the knowledge base used is domain-specific and 
therefore changes depending on the applied domain. Depending on the method, the input 
knowledge base can be a combination of rules, ontologies, or semantics. 
One of the most well-known TA methods is Y Shahar’s KBTA framework(23), 
developed in 1980s. In this framework the external knowledge base provides domain 
specific structural and semantic knowledge to perform TA tasks. It uses four domain 
specific knowledge types: structural, classification, temporal semantic and temporal 
dynamic knowledge. As another example, ChronoMiner developed by R. Raj(24) is an 
ontology-driven method, which uses a mining ontology as an input knowledge base to 
31 
 
mine patterns of HIV mutations associated with the drug-resistance from the time-
oriented research data. 
The abstractions produced by methods using a knowledge base are dictated and 
constrained by the input knowledge. Even though the TA methods that use a knowledge 
base can be applied across multiple domains using domain-specific knowledge, they 
require the knowledge to be maintained and kept up-to-date to produce accurate 
abstractions. Often a separate effort is established to acquire and curate the knowledge 
base for each domain of application; “Knowledge acquisition” as the step is termed in 
KBTA, involves collecting and curating the knowledge and building onto it moving 
forward; this step also involves amending or improving the existing pool of 
knowledge(25). 
3.1.3. Reasoning methods 
The reasoning methodology itself can be classified broadly into knowledge-driven 
and data-driven methods. A knowledge-driven method uses an external knowledge base 
as a guide to recognize abstractions from the input data and consists domain independent 
reasoning subtasks. A data-driven method, on the other hand, uses the input data itself to 
perform the abstraction task. The following two subsections describe the knowledge-
driven and data-driven TA approaches and corresponding examples. 
3.1.3.1. Knowledge-driven methods 
The knowledge-driven TA methods use domain-specific structural or ontological 
knowledge to perform generic TA tasks.  
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Shahar’s KBTA(23) method, for example, uses domain specific structural, 
classification, temporal semantic and temporal dynamic knowledge as its knowledge 
base. The KBTA method itself is decomposed into five sub-tasks: temporal context 
restriction, vertical temporal inference, horizontal temporal inference, temporal 
interpolation and temporal pattern matching. Each of these sub-tasks is solved by a set of 
corresponding domain independent rules. These sub-tasks produce abstractions of several 
types: state (e.g., high, low), gradient (e.g., increasing, decreasing), rate (e.g., slow, fast), 
and pattern (e.g., crescendo). The RESUME system(22) is an implementation of KBTA 
framework. The knowledge base for RESUME is called “TA ontology” and it defines 
ontologies of events (e.g., drug administration), of parameters (e.g., blood-glucose 
values), and of interpretation contexts. The RESUME system takes as input the time-
stamped patient data and clinical events, and produces abstractions that can be stored for 
additional analysis or for subsequent use by other applications. The TA mechanisms 
iterate alternately, activated by the input data and by the previously derived abstractions. 
This setup, as Shahar and Musen describe, makes KBTA versatile enough to be used over 
a variety of clinical domains(26).  
RASTA is another knowledge based approach developed by O’Connor et al(27). 
RASTA incorporates many ideas and concepts used by RESUME (which uses KBTA 
framework), and acts as a basis of a scalable architecture for performing temporal 
reasoning with clinical data. RASTA uses a distributed algorithm to allow independent 
evaluation of abstractions in abstraction hierarchies. The algorithm allows the 
methodology to work in parallel on very large datasets and supports varying 
configuration options to deal with different application requirements. RASTA uses an 
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“abstraction knowledge base” for input knowledge, which is a detailed description of all 
the temporal abstractions that it can perform in a particular domain with the time-stamped 
input data (termed as primitive data in RASTA terminology). The input data is assumed 
to be sourced from a relational database specified in the ‘mapping knowledge base’, 
which also specifies the database table and column name for each data component. Each 
piece of the input (primitive) data is time-stamped. The abstractions are associated with a 
particular context (another part of knowledge base) – a proposition that intuitively 
represents a state of affairs (e.g., an abstraction may be relevant only during the 
administration of a certain type of drug).  The TA algorithm itself, like the KBTA 
framework, contains four sub-tasks: context restriction, vertical temporal inference, 
horizontal temporal inference and temporal interpolation. 
Chkravarty et al. proposed CAPSUL(28) as a ‘pattern specification language’ to 
acquire and evaluate the knowledge for the knowledge base, and to perform TA by 
analyzing patterns among the time-oriented clinical data. CAPSUL allows the 
specification of components (what repeats), pattern constraints (how it repeats) and the 
corresponding context to define the ontology of patterns. CAPSUL allows 3 levels of 
constraints, local, global, and repeating, which are defined as ranges to enhance 
flexibility. Based on the given ontology of patterns (the knowledge base), CAPSUL relies 
on the RESUME system as its computational tool to perform the temporal abstractions. 
Abstractions are associated with respective rules that govern how they are derived from 
the input time-stamped data points for a given set of constraints. As is the case for 
RESUME, the newly created abstractions are added to a general pool of instances from 
which further abstractions can be derived. 
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3.1.3.2. Data-driven methods 
Data-driven methods rely on the content of the ‘input data’ to abstract and infer 
temporal information. These methods adopt statistical, machine-learning, or heuristic 
approaches for TA over the data.  
The data-driven methods adopting statistical approach use tools of regression 
analysis or association rules to perform TA. For example Lin et al. used logistic 
regression, association rule analysis and classification trees (a data mining technique) to 
impute associations between antiretroviral drugs administered (as a predictor) to the HIV 
patient and corresponding mutation of the HIV(29). The temporal analysis used was the 
time-window of drug administration and the extent to which the HIV mutated during that 
time. The temporal abstraction produced at individual patient level was the length of the 
time window and corresponding number of mutations in the HIV.  
Bramsen et al. used a supervised machine-learning approach to identify pair-wise 
temporal relations using temporal anchors(30). They used manually annotated samples 
for supervised training and used segment boundaries (events) and anchors (e.g., 
yesterday) to discern the relationship between events. This method would produce a set 
of event pairs and their temporal relationship identified by the method in terms of before, 
after and incomparable, along with a corresponding score (a higher score indicates higher 
confidence). The method may produce, for example, an event pair (insulin injection, 
blood glucose measurement) with a relationship of ‘before’ – indicating that the event 
‘insulin injection’ occurred ‘before’ the event of ‘blood glucose measurement’.  
A heuristic approach seeks to gather temporal information by exploration of 
possibilities, rather than following pre-set rules. Cousins et al. have used the temporal 
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granularity heuristics(17) to associate the level of importance of a medical event to the 
temporal granularity being considered. For example, even in an acute setting like an ICU, 
previously recorded information is manipulated at a different level of temporal 
granularity than the current events; also, once discharged from the hospital, the entire 
ICU course can be combined into a single abstract fact.  
Data-driven TA methods, unlike the knowledge-based methods, do not use any 
external reference to perform the task of abstraction. The abstraction task is performed 
either by using standard algorithms (e.g., statistical methods) or by using / following the 
features contained in the data itself. 
3.1.4. Output data 
Temporal abstraction methods can produce outputs of various types typically with a 
time interval temporal representation. The KBTA method is capable of producing 
temporal abstractions of interval, state, gradient, rate and pattern, depending on the 
application. The RESUME system(22), for example, produces temporal abstraction for 
chronic graft-versus-host disease (CGVHD). The abstraction (shown in Figure 5 of the 
paper) shows the respective grades for mylo-, platelet or granulocyte toxicity, along with 
corresponding trends of decreasing or increasing platelet and granulocyte counts. 
The RASTA system produces abstractions as structured data sets of temporal 
intervals. These abstractions are passed to the invoking application as a custom XML 
data structure or stored in a relational database. The output of CAPSUL is a set of 
interval-based abstractions (including pattern abstractions) that can be directly used by 
applications, or can be displayed and explored using visualization tool, such as 
knowledge-based abstraction visualization and exploration (KNAVE)(31). 
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Other customized TA applications, such as the temporal granularity heuristics 
created by Cousins et al. produces an output on a graphical user interface (GUI) to 
communicate the time-line of the events that can be interactively manipulated to varied 
degree of granularity and observe the events(17). The time-line of diabetes data for a DM 
patient shows events of illness, stress, hospitalization, along with varying levels of blood 
glucose. The ChronoMiner(24) by R. Raj also produces the GUI output showing the 
subject-wise longitudinal view of clinical data showing the viral load, mutations, the 
chronology of the drug treatment intervals for each drug. Such visual displays are 
informative and can communicate valuable information to clinicians.  
Bramsen et al. produce pair-wise temporal associations between events(30) and 
respective events as identified by the segmentations that can be useful for processing 
clinical narratives. The output abstractions produced by the KBTA based methods used 
by Shahar and Musen can be of different types, state, gradient, rate or pattern; and are 
determined by using goal-oriented task specific controls. 
3.1.5. Clinical domains 
Given the fact that patient health and medical data is time-sensitive, temporal 
representation and abstraction touches almost every domain of medical practice. There is 
a long history of using temporal abstraction methods in the domain of cancer dating back 
to the 1980’s. Kahn et al. developed TOPAZ(18) to interpret time-varying patient data for 
applications in cancer chemotherapy treatments and generate narrative summary of the 
temporal events found in the EMR. 
The KBTA method and CAPSULE have both been used for assessment of graft 
versus host disease in bone marrow transplant. The KBTA method has also been used in 
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the domain of therapy for insulin-dependent diabetes(26), and AIDS patients’ therapy(22; 
32). Levy’s Rule-based Response Assessment Method was used to classify tumor 
response to treatment in solid tumors and lymphoma(33). In the domain of medical 
research Lin et al.(29) and Raj et al.(24) have used customized TA methods to study HIV 
mutations associated with drug-resistance. Shahar and Musen reason(34) that clinical 
guidelines are a common format in medical domains (be it oncology, AIDS, or diabetes) 
for prescribing a set of rules and policies that a provider should follow. They have 
demonstrated that automated support for clinical guidelines could be enhanced 
considerably by formal representation of therapy-planning-operators’ efforts, plan-
revision strategies, and the underlying goals and policies of the guideline in the form of 
temporal abstraction patterns to be maintained, achieved or avoided.  
TA is a very useful mechanism available to analyze medical information. With the 
advent of EMR systems, it is imperative that various applications of TA can be designed 
and devised. Adlassnig et al.(20) have provided a detailed account of promising 
directions of research in the field of temporal representations and reasoning in medicine, 
and Augusto(19) suggests that more research is needed to make time-based systems for 
widespread use in medicine. 
3.2. Limitations of prior work on temporal abstraction 
The existing methods such as those based on KBTA(23)
, 
(26), use external 
knowledge base as a reference to perform TA. To accomplish the TA task accurately, 
these methods require a carefully compiled and curated knowledge base. Additionally 
they need to continually maintain this knowledge base to keep it up to date. The tasks of 
knowledge acquisition and evaluation require the creation of the additional elaborate 
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tools. In the cancer domain itself, as was discussed in chapter 2, there are over one 
thousand protocols of chemotherapy treatment(9) with several thousand more under 
investigation in therapeutic clinical trials(35). If a knowledge-based TA method were to 
be used for chemotherapy plan abstraction, it would require maintaining a knowledge 
base of all these chemotherapy protocols and regular updates that result from the 
developments of the new protocols culminating at the end of the clinical trials in 
progress. This regular maintenance of a knowledge base requires significant effort from 
experts in various cancer domains.  
Other TA methods have restricted application for detecting patterns from the input 
events and are otherwise not generalizable or reusable methods. The data-driven method 
for prediction of HIV mutations by R. Raj(24), for example, indicates only temporal 
association between the HIV mutations and corresponding treatment. It is used as a 
preliminary step to provide predictors for domain experts to perform confirmatory 
analysis. The elegant interface produced by Cousins(17) for display and manipulation of 
temporal information does a very good job of displaying temporal events in appropriate 
sequence, but achieves little in creating patterns at the output with associated attributes to 
aptly describe features of the distinct treatment plans abstracted from the input events. 
The data-driven method for finding temporal order in discharge summaries by 
Bramsen(30) is also restricted to indicating temporal association between two events in 
terms of their relative temporal order. 
3.3. Informatics opportunity 
Considering the limitations of the knowledge-based TA methods, there is an 
opportunity to create a data-driven plan abstraction method that does not rely on external 
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knowledge base to abstract medication plans. In an ICU setting knowledge-based and 
data-driven methods were used for TA to derive features that would be used to predict 
whether postsurgical patients needed mechanical ventilation (MV)(36). The knowledge-
based method uses knowledge from practitioners to derive qualitative patterns of state 
changes. The data-driven method, on the other hand, searches through a large number of 
data summaries to discover those that have predictive value for the need for MV. An 
assessment of the two methods by Verduijn showed that the knowledge-based method 
had better sensitivity, with a lower misclassification rate. Moreover, the data-driven 
method provided additional statistical summaries.  
In addition to the need for an integrated solution for a plan abstraction method at 
clinical level, it is expected that such a tool would be useful in performing cohort 
analysis. As described in chapter 2, the task of extracting treatment history for individual 
patients in a cohort study is laborious, lengthy and costly. A tool that can abstract 
treatment history from distinct medication events can prove to be a valuable resource.  
 
  
 CHEMOTHERAPY PLAN 
The chemotherapy plan 
and produces as output a sequence of patient level 
plans can be used for patient care and research, or 
analysis method. 
 
Figure 4.1. Schematic of chemotherapy plan abstraction method
The pre-processing module takes its input from a data source residing in the EHR 
(Electronic Health Record) and produces standardized, time
event data. The plan abs
data as input and produces patient level plans as output. These plans can be 
analyzed at the cohort level to provide informative aggregate data.
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The development approach was to create a 
set of time-stamp medication events, detect temporal patterns
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medication plans at the output. The method uses a ‘data-driven’ knowledge base (KB) to 
refine the plans before delivering the plans as output. Figure 4.1 shows the schematic of 
this approach. Depending on the particular requirements of the data source for medication 
events, a corresponding pre-processing module creates standardized medication event 
data that can be used as input to the method. The chemotherapy plans and corresponding 
information attributes that the method produces provide valuable information to the 
practicing oncologists. This information, when considered collectively over patient 
groups, can serve as input for cohort level analysis.  
4.2. Pre-processing of data 
The method expects the medication events to have a minimum of three important 
attributes, Patient ID, Drug Name, and the date-time stamp of drug administration. Very 
few data repositories in EHR subsystems can provide medication event data with these 
attributes without some amount of pre-processing. A pre-processing module imparts 
flexibility to the method by enabling it to read input data from disparate sources. Pre-
processing incorporates filtering, cleansing and transforming of the input data to 
accommodate variances inherent in the sources of data. 
4.2.1. Data Sources 
Table 2.1 summarizes the various clinical data sources available at the Vanderbilt 
University Medical Center (VUMC) (denoted by a “V”) that could be used to extract 
medication events. 
At the time of this study, these data sources were available with variable 
completeness (denoted by the “%”). Specifically, bar-coded nursing administration 
records were not available for the patients treated in the outpatient cancer infusion center, 
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where the vast majority of cancer drug therapies are administered. Pharmacy dispensing 
records, however, were available electronically for both the outpatient and the inpatient 
population, providing a complete record of the chemotherapy medications administered 
to the cancer patients at our institution. The pre-processing method discussed here creates 
well-formatted medication events from the pharmacy transaction database for use as 
input to the CPAM. 
4.2.1.1. Pharmacy database and the Synthetic Derivative 
The Enterprise Data Warehouse (EDW) at the VUMC contains the schema where 
pharmacy transaction data are stored. Four DB tables in this schema contain the 
medication dispensing information. The EDW, however, contains patient identified data. 
To develop and test the plan abstraction method while maintaining patient privacy, we 
chose to de-identify the pharmacy datasets used for training and testing the method. At 
the same time, we took the opportunity to incorporate the comprehensive version of the 
de-identified pharmacy data into our institution’s de-identified synthetic derivative of the 
EHR.  
In 2006, the VUMC began the effort of creating a comprehensive de-identified 
relational research database called the Synthetic Derivative(37) (SD).  The SD contains 
clinical data (physician notes, orders, diagnoses, lab tests, etc.) in de-identified form(38), 
derived from the VUMC’s EHR; all the personal information from the EHR is stripped, 
and dates shifted (synthesized) before it is inserted into the SD.  
The SD makes use of DE-ID, a commercially available licensed de-identification 
tool, to scrub EHR records of the 18 HIPAA safe harbor provisions, along with the other 
significant pre- and post-processing techniques. The de-identification process ensures that 
 the corresponding relevance of attributes to individuals is maintained, but re
identification (reverse of de
(MRNs) identifying individual patients are replaced by respective 
(RUIDs), and dates (of birth, admission, discharge, diagnoses, etc.) are randomly shifted. 
To ensure temporal relativity of the dates 
the date shift is consistent for a given patient. 
approval, which was obtained for this study
 
Figure 4.2. SD and Tumor Registry
Figure showing pharmacy dispensing records set in SD and corresponding overlap 
with the Tumor Registry data in terms of number of patients that have respective 
data in either sets. SD = Synthetic Derivative.
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SD has been used as a stand-alone resource for clinical research. The Vanderbilt Ingram 
cancer center (VICC) tumor registry (TR) data for over 62,000 patients has recently been 
added to the SD, to enhance cancer research. As part of research effort for this thesis, 
pharmacy data was added to the SD consisting of 17,645,747 charged item records 
between January 2, 2006 and May 22nd, 2011. Figure 4.2 shows the pharmacy 
dispensing records set and the TR data set, and the number of patients with data in both 
sets. 
4.2.2. Data extraction and processing methods 
For the purpose of testing the chemotherapy plan abstraction method, only 
medication dispensing transactions pertaining to chemotherapy drugs were extracted. 
Vanderbilt's pharmacy system uses National Drug Codes (NDC) as its controlled 
terminology for representing drug concepts. A sub-set of these codes is manually 
classified as "cancer drugs" for operational purposes.  This classification was used as a 
reference to filter the pharmacy dispensing records for chemotherapy drug instances. A 
single de-normalized dataset of chemotherapy drug events was extracted from the 
pharmacy data in the SD. Each record in the dataset had the following attributes: 1) a 
surrogate of patient identifier, 2) name of the drug, 3) NDC identifier, 4) drug dose, 5) 
frequency at which the drug is to be administered, 6) route of administration, 7) the 
quantity of the drug dispensed, 8) the dollar amount charged to the patient’s account, 9) 
the date-time-stamp of the charge, and 10) the date of charge. The date-time-stamp of 
charge corresponds to both the pharmacy dispense date and the nursing drug 
administration date. 
 This marked the starting point 
module. Figures 4.3 and 4.
pharmacy dispensing data from the EDW
eliminating canceled orders
names, and 4) drug dose consolidation. 
 
Figure 4.3. Schematic of preprocessing steps
Pharmacy dispensing records extracted from EDW (Enterprise Data Warehouse) 
are de-identified using commercial software DE
Derivative). The pre
events from pharmacy dis
filters. The chemotherapy drug events are then normalized through several pre
processing steps including 1) eliminating cancelled drug orders, 2) removing oral 
drugs events, 3) normalizing drug names, and
end, the pre-processing module produces time
are used as input to the plan abstraction method. [The numbers at respective steps 
indicate the patients and corresponding medication events.
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Eliminating canceled orders: Pharmacy systems are clinical transaction systems that 
allow the pharmacy department to record and store orders and bill for the dispensed 
medications. If the order is valid when the patient presents to the infusion center to get 
their medication, the nurse administers the medication and the corresponding charge is 
processed by the billing system. If due to some reason the dose needs to be changed or 
the medication canceled, the pharmacy system records that cancellation as a reversal of 
the charge for that dispensing event. A small proportion of the transactions have positive 
as well as corresponding negative charge records. To eliminate these canceled orders, the 
pre-processing method groups the pharmacy records by patient, drug name and credit 
date of charge. The corresponding charge amounts are aggregated to obtain the net 
amount charged for a given drug-dispensing event. Dispensing events with a net zero 
charge were eliminated, since they represent cancelled orders, as illustrated in figure 4.4 
drug B is eliminated because B+ and B– charges for drug B result in 0 net charge. 
Removing records with oral drugs: Anti-cancer therapies that are given orally are 
typically taken at home daily or for several consecutive days. Most of these therapies are 
not dispensed by the hospital chemotherapy pharmacy but rather by the patient’s 
preferred outpatient pharmacy. Rarely, these drugs are dispensed by the hospital 
chemotherapy pharmacy when the patient is admitted to the hospital or on a research 
protocol. Since these events were rare and did not represent a complete history of oral 
anti-cancer therapies prescribed to our patient population, they were eliminated for the 
purpose of this analysis. All the dispensing records with oral administration route 
(attribute ROUTE with either of these values – ‘ORAL’, ‘PER TUBE’, ‘PO’, ‘PO/PT’ – 
 which are all equivalent of oral route) were therefore removed. As illustrated in figure 
4.4, drug F with oral route is removed.
 
Figure 4.4. An illustration of 
A reference of internal codes for chemotherapy drugs is used to select 
chemotherapy dispensing events from the pharmacy dispensing data in SD. After 
that the events go through 1) charge consolidation to get the net
canceled orders
used common names by referencing the preferred drug
practicing oncologist) and
time-stamps for the drug
for a given patient and 
at the same time for a given patient. 
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variants to respective common terms, distinct drug names were extracted from the initial 
dataset. A practicing oncologist manually mapped the synonyms to a common preferred 
drug term. The original dataset was then augmented with a new attribute – 
DRUG_NAME_USED; for each record with drug name variant, the corresponding 
preferred term was assigned to this new attribute. As illustrated in figure 4.4, Drug E is a 
variant of drug B and therefore name B is assigned to this drug. For example, drug names 
Docetaxel and Docetaxel (Taxotere) are both equivalent to Docetaxel; therefore the name 
Docetaxel assigned to the new attribute DRUG_NAME_USED for both cases. 
Drug dose consolidation and controlling temporal granularity: Some medication 
orders have multiple dispensing records in the pharmacy system because the total dose of 
a given medication order is dispensed in multiple vials. Depending on the quantity of the 
drug ordered, the corresponding transactions are appropriately split if it exceeds the 
constrained size. Also, the finest granularity of administration event frequency considered 
for this method is one day. Any given drug with multiple doses dispensed on the same 
day, for a given patient, is counted as a single drug event in the temporal sequence of 
drugs administered to the patient. This was done by assigning the earliest date-time stamp 
to the group of records that matched for the patient, drug name and dispense date. For 
example, drug B in figure 4.4 (which was originally named drug E) is dispensed as two 
separate doses on the same day. It is consolidated into a single dose, with the earliest 
time-stamp of the two. As an example, the drug Doxorubicin is typically dispensed in two 
vials, corresponding to a single dose administered to a patient. These two dispensing 
events were consolidated into a single dispense event. 
 At the end of the pre
chemotherapy drug events for 7,805 distinct cancer patients
months, with the following attributes
drug (with common terminology)
 
Figure 4.5. Plan abstraction Method steps.
1) Assign day number, 2) group same day events, 3) group successively recurring 
events, 4) identify
knowledge base (KB). 
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Figure 4.6. Steps 1 and 2 of 
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relative day number.
Step2 – Grouping same day eve
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number of 1 with each successive event numbered based on its date relative to the earliest 
event. This step thus converts absolute time instances into their corresponding relative 
time instances. For example, as shown in figure 4.6, the earliest drug event for Cisplatin 
occurring on 2008-07-29 is assigned the day number of 1. A subsequent event occurring 
on 2008-08-19 is assigned the day number of 22, that date being the 22
nd
 day from 2008-
07-29. Events occurring on the same day are assigned the same day number; for example, 
events for Bevacizumab, Carboplatin and Paclitaxel occurring on 2008-09-30 are all 
assigned the day number of 64. 
Step 2: Group the same day events 
In this step, the events occurring on the same day are grouped together to form a 
common event and the corresponding drug names are concatenated. Before 
concatenating, the names are capitalized and abbreviated to the first four characters, and a 
‘+’ sign is used as a separator between consecutive drug names. Figure 4.6 highlights 
these actions. For example events for the drugs Cisplatin and Etoposide occur on the 
same day; these events are merged together as a single event. The drug names are 
abbreviated to CISP and ETOP respectively, concatenated and separated by a ‘+’ sign.  
Abbreviating the drug names and concatenation thereof with a ‘+’ separator creates a 
new vocabulary for the CPAM. 
Step 3: Group the successively repeating events 
By this step, for a given patient on any given day, only a single event comprised of 
one or more drugs remains. With the events arranged in chronological order, the method 
looks for successively repeating events. Each group of repeating events is merged 
 together into a single record instance. For example, as shown in figure 4.7, events for 
Etoposide (ETOP) repeat twice and are merged into a single instance with a relative date 
of ‘2, 3’ as an attribute. As another example, events comprising
Bevacizumab (BEVA), Carboplatin (CARB) and Paclitaxel (PACL) are merged together 
into another single record instance of drug combination BEVA+CARB+PACL, a 
chemotherapy plan commonly prescribed to lung cancer patients. Several new attributes 
are created at this step including 
carried forward to the next step (and defined in table 4.1). Simple plans start emerging at 
the end of this step, but more complex plans require additional processing.
Figure 4.7. Step 3 of CPAM.
Group the successively repeating events
merged into a single instance with corresponding start
number of cycles.
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52 
StartDate, DayString and (number of) Cycles
 
. Events that repeat successively are 
-date, day
  
 
attempts to detect the repeating patterns of drugs among the 
in the previous step. As shown in figure 4.
 of the drugs 
, which are 
 
 
-sequence and 
8, the 
53 
 
pattern consisting of an instance of CISP+ETOP followed by an instance of ETOP is 
repeating twice. Record instances exhibiting such patterns are merged together with 
corresponding pattern constructed. For example, the pattern of CISP+ETOP followed by 
ETOP is constructed as “CISP+ETOP, ETOP”, where a comma (“,”) separates each drug 
component in the pattern. This is another example of the emerging vocabulary for this 
method. Whenever such patterns are identified corresponding record instances are 
merged and several attributes are re-computed as described in table 4.1. Any records not 
participating in pattern sequences are carried forward unaffected. For example, as shown 
in figure 4.8, the record instances consisting of the drug group CISP+ETOP and another 
one consisting of the drug group BEVA+CARB+PACL. 
Step 5: Consolidate partial patterns 
Close examination of step 4 output reveals some plans that appear similar to other 
plans, but are somehow incomplete. For example, the record corresponding to plan 
‘CISP+ETOP’ (the second in the list at step 4 of figure 4.8) appears to be an incomplete 
version of the previous plan ‘CISP+ETOP, ETOP’. This could have happened due to the 
patient intolerance to the toxicity of the drugs and thus likely represents an incomplete 
cycle of the same plan. To be able to infer such incomplete or non-repeating complex 
patterns as plans, a list of distinct plans is compiled at the end of step 4. Every record 
produced at the end of step 4 that repeats more than once (attribute value for Cycles > 1) 
is classified as a plan at this stage and included in a data-driven knowledge base (KB). 
Non-repeating plans may be incomplete plans and are thus not included in this list. For 
example, in figure 4.8 plans ‘CISP+ETOP, ETOP’ and ‘BEVA+CARB+PACL’ are 
added to this knowledge base. 
  
Figure 4.8. Steps 4 and 5 of CPAM
Step 4: Identify patterns
the record instances produced by the previous step. For example, the pattern 
CISP+ETOP, ETOP is seen repeating twice. Record instances for these patterns are 
grouped together and corresponding 
attributes are computed as described in table 4.1. [KB = Knowledge Base]
Step 5: Consolidate partial plans
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marked with an asterisk, indicating that the last cycle of the plan was incomplete. The 
drug-sequence in the plan is modified, enclosing the component that was missing in the 
last cycle with a pair of braces. The marking of ‘cycles’ string with an asterisk and 
enclosing the missing drug-component with braces is yet another example of new 
vocabulary used by the method to communicate specific meanings. 
The output of the chemotherapy plan abstraction method is a set of structured data, 
with each record representing an abstract form of chemotherapy plan inferred from the 
input data of distinct chemotherapy drug events. A new ‘vocabulary’ is devised to convey 
specific and helpful details for each of the plans. The abstract versions of the plans 
produced by the method are accompanied by a rich set of attributes that are consistent 
with those suggested by ASCO in their treatment summary guidelines(3). A complete list 
of attributes that is produced by the method, for each plan, is given in table 4.1 along with 
the corresponding description. 
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Table 4.1. Plan attributes produced by chemotherapy plan abstraction method. 
Attribute Description 
Patient Id Surrogate identifier of the patient for whom the chemotherapy plans 
are produced from the corresponding drug events. 
Serial Number For a given patient this is a running number assigned to each plan, 
from the earliest to latest, starting with 1. SerialNumber facilitates a 
simple way of assigning cardinality and order to the set of plans for a 
given patient. 
Drugs The string listing the chemotherapy drugs that constitute the plan. 
Individual drug components are separated by comma (‘,’). Each of the 
drug components themselves may consist of multiple drugs – when 
multiple drugs are administered on the same day – in which case these 
drugs are separated by “+” sign. 
Cycles This is the number of cycles by which the chemotherapy plan repeats. 
In case of the compound plans (plans consisting of multiple drug 
components separated by comma) this attribute is a set of cycles 
delimited by comma and enclosed in a pair of parentheses – with each 
component within the parentheses having one-to-one correspondence 
to the drug-component in the plan. This string represents the dose 
count of the first dose set of the drugs. The total number of cycles for 
the compound plan is indicated by the right-most numeric, outside the 
parentheses and separated by ‘x’ from the parenthesized set, and 
indicates the number of times for which the whole plan is repeated. In 
cases where the last cycle of a compound plan is incomplete (as shown 
in figure 4.8) an asterisk appears at the end of this attribute. 
StartDate This is the date when the first drug event of the chemotherapy plan (as 
listed in the attribute Drugs) was started. 
StartDay This is the day number corresponding to the StartDate of the plan 
DayString The string of day numbers when the drug-events corresponding to this 
plan occurred. For a compound plan, this attribute is a set of day 
number values enclosed in a pair of parentheses and delimited by 
comma – with each component having one-to-one correspondence to 
the drug-component in the Drugs string.  
DaysToChange For a given patient, this is the number of days between the StartDate 
of the current plan and that of the one immediately prior. [By 
definition, this attribute will have meaning only for the plan records 
with SerialNumber > 1.] 
DaysBetween For a given patient, this is the number of days between StartDate of 
the current plan and the last drug event of the one immediately prior. 
Periodicity This is the periodicity with which the chemotherapy plan is repeated. 
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CHAPTER 5  
EVALUATION 
 
The evaluation of the CPAM consists of an assessment of its accuracy and utility for 
cohort plan analysis. The former evaluates the extent to which the method correctly infers 
patient level treatment plans. The later analyzes the concordance of the method’s cohort 
level output with expected standard of care chemotherapy protocols.  
5.1. Evaluation of patient level performance 
The chemotherapy plan abstraction method was iteratively trained using a manually 
curated gold-standard training set of chemotherapy drug events for breast and lung cancer 
patients. The method was then tested on two manually curated datasets of chemotherapy 
drug events for 1) breast and lung cancer patients and 2) non-breast, non-lung cancer 
patients. 
5.1.1. Training and testing data sets 
The training and testing data sets were derived from the pharmacy-dispensing 
database in the SD.  Specific subsets were grouped by cancer diagnosis as determined by 
the tumor’s site and histology from the tumor registry data.  Table 5.1 shows the counts 
of patients and corresponding drug-events used in the training and testing data sets for the 
CPAM. 
To ensure that the method could satisfactorily process the drug events for mixed 
cancer domains, the initial training and testing data sets consisted of patients with either 
lung cancer or breast cancer. The initial training set consisted of 163 patients with 2,402 
chemotherapy drug events before pre-processing and 2,298 events after pre-processing.  
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Similarly, Test Set 1 consisted of 341 breast and lung cancer patients with 5,713 
chemotherapy drug events after pre-processing. 
  
Table 5.1. Training and testing datasets. 
Training and testing data sets including a description of the cancer domain covered, 
the patient count, and the drug events counts before and after the pre-processing. 
  
Training 
set 
Non-trained test sets 
Test set 1 Test set 2 
Test set 2 
(Sample for 
evaluation) 
Cancer Domain 
breast & 
lung 
breast & 
lung 
non-breast/non-lung solid 
tumor  
Patient count 163 341 7,805 168 
Pre-filtered drug events 2,402 6,050 139,659 3,366 
Pre-processed drug events 2,298 5,713 136,998 3,214 
 
To test the generalizability of the CPAM, a testing set was created of patients with 
non-breast, non-lung cancer solid tumors. 7,805 patients with 136,998 chemotherapy 
drug events were identified in the SD. A random sample was draw from this data set to 
create Test set 2.  The size of the statistically relevant random sample was estimated by 
taking into account the expected performance of the method. Based on earlier tests, the 
recall and precision values of 0.8 each were considered. Using these values for either of 
the characteristics, the sample size figure of 300 was obtained [using proportionality test 
function prop.test of statistics package R - version 2.12.2 (2011-02-25)], with a 95% 
confidence interval of (0.7493, 0.8428). This suggests that if the true recall and precision 
of the method were to be 0.8 each, for any random sample of 300 plans obtained at the 
output of the method, these parameters would evaluate to be between (0.7493, 0.8428) 
95% of the time. Though the calculated sample size was 300 plans, drawing a set of 
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exactly 300 plans from the output was not feasible, since for a given patient, all or no 
plans needed to be included. The resulting testing set consisted of 306 plans for 168 
cancer patients. 
After applying the CPAM to both the training and the testing sets, a trained medical 
oncologist manually classified the output to create the gold standard. The oncologist 
compared the individual plans and the corresponding input medication events for each 
patient, marking each abstracted plan as a true positive (TP), false positive (FP), or false 
negative (FN) plan. For example, if the method produced multiple output plans for what 
should have been a single plan, each abstracted plan would be classified as a false 
positive plan. Likewise, the collection of FP plans would be classified as single false 
negative plan corresponding to the actual plan that was not detected. 
 
Table 5.2. Performance results of the CPAM. 
Performance results of the CPAM showing the recall, precision, F1-score and 
accuracy for the training test set and the two non-trained test sets. 
Training test set 
(95% C.I.) 
Non-trained test sets 
(95% C.I.) 
Test-1 
Test-2 
(Sample) 
Recall 
0.888 
(0.8432, 0.9223) 
0.913 
(0.8870, 0.9329) 
0.899 
(0.8537, 0.9316) 
Precision 
0.752 
(0.6996, 0.7973) 
0.829 
(0.7989, 0.8563) 
0.755 
(0.7020, 0.8012) 
F1-Score 0.814 0.869 0.821 
Accuracy 
0.687 
(0.6348, 0.7346) 
0.768 
(0.7361, 0.7979) 
0.696 
(0.6427, 0.7442) 
 
5.1.2. Performance results of the plan abstraction method 
Table 5.2 shows the performance of the CPAM for the training and testing data sets 
along with their respective confidence intervals. The original training set had a recall rate 
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of 88.8%, a precision of 75.2% and an accuracy of 68.7%.   For the testing round, test set 
1 had a recall rate of 91.3%, a precision of 82.9% and an accuracy of 76.8%.  Test set 2, 
had a recall rate of 89.9%, a precision of 75.5% and an accuracy of 69.6%. The results for 
test set 2 represent generalized performance of the chemotherapy plan abstraction method 
for solid tumors with a confidence level of 95%. 
5.2. Cohort level plan analysis 
One of the primary goals of the CPAM is to extract sequences of patient level 
chemotherapy protocols from discrete medication events for cohort level analysis. The 
second part of the evaluation process demonstrates a simple use of cohort level analysis 
to evaluate the practice patterns and the variance in plan adherence for several 
chemotherapy plans as compared to the standard of care. For a single disease breast 
cancer, we demonstrate an across plan analysis comparing the frequency of the plans 
administered, and a within plan analysis to understand variances in the administration of 
a single plan. 
5.2.1. Across plan analysis 
The first analysis assessed the most frequently administered chemotherapy protocols 
for a cohort of breast cancer patients at the VUMC.  This gives insight into the practice 
patterns for this disease at our institution.  A cohort of 554 breast cancer patients treated 
with chemotherapy was isolated in the SD using a combination of the tumor registry and 
the pharmacy data sets.  For this set, a list of abstracted chemotherapy plans was created 
along with the count of patients receiving each plan, and ordered by descending patient 
count.  For this cohort, 107 unique breast cancer plans were identified. Table 5.3 shows 
the 5 most frequently prescribed plans. A full list of breast cancer plans abstracted by the 
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CPAM is listed in Appendix A.  The most commonly administered plan in this cohort 
was an adjuvant therapy protocol Cyclophosphamide + Doxorubicin, received by about 
36%. of patients.  In comparison, the 5
th
 most commonly prescribed plan, an adjuvant 
protocol consisting of the drugs Cyclophosphamide + Docetaxel, was administered to 
only about 8% of this population.  This demonstrates a clear dominance of the 
Cyclophosphamide + Doxorubicin adjuvant therapy protocol among this group of breast 
cancer providers. 
 
Table 5.3. List of five most frequently administered chemotherapy plans for breast cancer. 
Five most frequently administered chemotherapy plans showing corresponding 
patient count along with average and standard of care figures for number of cycles 
and periodicity. The line of therapy column indicates whether the corresponding plan 
is used for adjuvant or metastatic treatment (or both). The values in columns with 
grey-background are provided by a practicing oncologist. 
Name 
Chemotherapy 
Protocol 
Patient 
Count 
  Periodicity (days) Number of Cycles 
Line of 
therapy 
Standard 
of Care 
Average 
(Min, Max, SD) 
Standard 
of Care 
Average 
(Min, Max, SD) 
Cyclophosphamide, 
Doxorubicin 198 Adjuvant 14 
15.8 
(7, 28, 3.1) 4 
3.6 
(1, 6, 0.9) 
Paclitaxel 138 
Adjuvant, 
Metastatic 7 
10.6 
(6.4, 29.4, 4.7) 
12, 
Unlimited 
7.1 
(1, 16, 4.3) 
Trastuzumab 61 
Adjuvant, 
Metastatic 7, 14, 21 
22.1 
(7.8, 63, 8.6) 
1 year, 
Unlimited 
9.0 
(1, 64, 11.1) 
Fulvestrant 55 Metastatic 28 
27.3 
(13, 107, 16.6) Unlimited 
6.4 
(1, 53, 8.5) 
Cyclophosphamide, 
Docetaxel 46  Adjuvant 21 
21.7 
(20, 29.7, 1.8) 4 
3.7 
(1, 6, 1.0) 
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Figure 5.1. Line of therapy bar-plot for the two most frequently administered breast cancer 
plans. 
The line of therapy bar-plot shows that most of the patients receiving the 
“CYCL+DOXO” plan received it as the first line of therapy, and most of those 
receiving “PACL” plan received it as the second line of therapy. 
 
The sequence of plans also gives insight into provider adherence to standard of care 
protocols.  Figure 5.1 shows the bar chart for the sequence of therapy for the two most 
frequently administered breast cancer plans. The sequence of therapy, represented by the 
Serial Number attribute produced by the CPAM indicates whether the plan was given 
first, second or third in sequence for a given patient. As is consistent with the clinical 
practice, the Cyclophosphamide + Doxorubicin plan is typically the first plan to be 
administered in the adjuvant setting(39). Depending upon the clinical context, the 
Paclitaxel plan is typically administered second following the Cyclophosphamide + 
Doxorubicin plan in the adjuvant setting(39)
, 
(40) or as a first line of treatment in the 
metastatic setting(41).  This analysis demonstrates both that the CPAM produces results 
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concordant with what is expected for standard of care, and that the VUMC practice 
patterns are likewise concordant. 
5.2.2. Within plan analysis 
A within plan analysis also provides insights regarding plan adherence. As discussed 
in earlier chapters, patient toxicity may require deviation of the actual chemotherapy drug 
administration events from the planned periodicity and cycles defined by a chemotherapy 
protocol. Table 5.3 shows the observed average periodicity and number of cycles 
compared with the corresponding standard of care values for the five most frequent breast 
cancer plans. 
The statistical parameters, including the standard deviation were calculated for each 
plan over the respective number of patients. A trained medical oncologist defined the 
corresponding standard of care values. Figure 5.2 shows violin plots of the observed 
values for periodicity and cycles for the two most frequently prescribed plans, 
“Cyclophosphamide + Doxorubicin” and “Paclitaxel” [statistics package R, version 
2.12.2 (2011-02-25).] Over each of these violin plots, a reference line is drawn in red 
corresponding to the standard of care value and another line in green showing the average 
for the dataset. The distribution plots for “Cyclophosphamide + Doxorubicin” exhibit a 
pronounced modality at or near the standard of care values, indicating a close 
concordance to the respective standard of care values for this treatment plan. 
 
 Figure 5.2. Periodicity and # of Cycles distribution for the two most frequently administered 
breast cancer plans.
Violin plots showing the distribution of the f
cycles for respective patient cohorts receiving one of the two most frequently 
administered chemotherapy plans for breast cancer.
 
For the second most common plan 
number of cycles both show a bimodal distribution. 
cycles and another at 12 cycles; and
another near 14 days. These plots suggest
containing the single agent 
standard of care protocols for Paclitaxel, one where Paclitaxel is given every two weeks 
for 4 cycles(39) and the other where it is given 
 
 
64 
 
igures for periodicity and 
  
“Paclitaxel”, however, the periodicity and 
The cycles plot exhibits a
 the periodicity plot exhibits a bulge near 7 days and 
 the possibility of two different plans
Paclitaxel. This information is consistent with two known 
weekly for 12 cycles(42). 
 
 
number of 
 bulge at 4 
, both 
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CHAPTER 6  
DISCUSSION 
 
The CPAM takes as input time stamped medication events and produces as output 
abstract level medication plans using a data-driven approach. This method has clinical as 
well as research applications. This chapter discusses the contributions of the CPAM to 
informatics and medicine, and its limitations. 
6.1. Informatics contributions 
The need for abstraction of temporal data is often encountered in medicine. Even 
though a wide literature concerning temporal abstraction is cited in various medical 
domains, processing the temporal data still remains a challenge(43)
, 
(19) due to the varied 
and interacting clinical dimensions involved (e.g., disorders, treatments, disease states). 
As referenced in this text earlier, there have been several proposals towards the 
framework of the knowledge-based approach for temporal abstraction and its 
applications. Though there are fewer references concerning data-driven approach to 
temporal abstraction, the efforts(36) in that direction are rapidly evolving(43). 
6.1.1. Data-driven approach 
Data-driven methods have the advantage of not requiring extensive knowledge 
acquisition and continued maintenance. Data-driven methods rely on and derive their 
knowledge from the features and content of the data provided as input. The CPAM 
performs reasonably well without the need for a manually derived knowledge base. 
Because the method does not rely on any external knowledge base, it is not limited by 
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any rigid rules pertaining to the specific parameters of the plans it abstracts as to the 
ranges of variations in periodicity or number of cycles it can detect. 
6.1.2. Simplicity of the method 
The CPAM is a simple heuristic approach that derives its knowledge base from the 
input data. The method does not use any complex mathematical algorithms or 
sophisticated probabilistic analysis; it uses basic grouping, pattern identification and 
matching processes. Due to the simplicity of the implementation, the method does not 
have any specific software or hardware constraints. It can be implemented in any 
environment and expected to perform equally well in terms its outcome. The performance 
speed of the method is also scalable with the bulk of input data. During this project, the 
final data bulks given as input to the method were more than 50 times larger than the 
initial input data and the method performed well without degradation in processing time. 
The versatility of the method also lies in its flexibility to accept data from a variety 
of input sources. Given appropriately formulated pre-processing steps, it can take 
chemotherapy event data input from any of the clinical sources discussed in chapter 2. 
6.1.3. Secondary use of pharmacy data for research 
In addition to the development of the CPAM, this work has enabled secondary use of 
Vanderbilt’s Pharmacy transaction database for research. Implementation of 
computerized pharmacy dispensing record systems is widespread, and the data stored in 
such systems is in a structured format. Prior to the development of the CPAM the 
pharmacy dispensing records data were only available to researchers via the enterprise 
data warehouse (EDW) with all the patient health information (PHI) intact. As part of the 
CPAM development effort, and to be able to provide sufficient data bulk, the SD 
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database was expanded to include the pharmacy dispensing records data in a de-identified 
form. This facilitated the use of pharmacy data for wider use by the Vanderbilt research 
community. 
6.2. Informatics limitations 
The CPAM has several limitations including issues related to controlled 
terminologies, pattern detection, and the lack of a query tool.  
6.2.1. Drug terminology limitations 
Medications often have several clinically relevant synonyms including the generic 
name (e.g., Vemurafenib), brand name (e.g., Zelboraf), and names used during drug 
development (e.g., PLX4032). In addition to variations in drug name, there are several 
widely used drug terminologies that create unique identifiers including RxNorm and 
NDC to name a few.  Clinical information systems use a variety of drug name and drug 
coding terminologies along with institution specific variations.  For instance, where 
possible, the VUMC pharmacy information system uses the First Databank (FDB) drug 
knowledge base as its reference terminology including the generic and brand drug names 
as well as the NDC codes.  However, knowledge bases such as FDB often lag in their 
representation of investigational agents that have not yet been assigned an NDC.  In order 
to process investigational drugs using the PIS, a custom term is created often with a non-
specific NDC and a custom generated name.  In the VUMC system for instance, the word 
‘INVEST’ (for investigational) is appended to the end of the drug name. This allows the 
pharmacy to bill appropriate drug supply for a clinical trial. 
The current implementation of the CPAM has several limitations with respect to the 
pre-processing approach to drug name normalization. First, it does not use a controlled 
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drug terminology to identify anti-cancer drug names by class. The current 
implementation leverages an existing manually annotated list of anti-cancer drugs 
specific to the VUMC pharmacy system. While this manually annotated list is 
continuously updated for operational purposes, this approach limits the generalizability of 
the method to other data sources, including pharmacy data sources from other 
institutions. Second, the method does not use a controlled terminology to identify drug 
name synonyms. Instead, a manual process was required to map drug name synonyms to 
a common preferred term. Given that several of the drugs were investigational agents, a 
combination of the RxNorm and National Cancer Institute Thesaurus (NCIT) 
terminologies could be leveraged to generalize the approach. 
6.2.2. Limitations in pattern detection 
The CPAM is based on the assumption that groups of medications are given as 
repeating events. This is an appropriate assumption for many oncology treatments that 
often repeat but may be less relevant for other diseases. However, there are some 
complex cancer treatments that span several consecutive days with multiple drugs that do 
not repeat, especially in hematologic malignancies. Due to the assumption that all plans 
must repeat for a patient, the CPAM does not recognize the non-repeating plans correctly. 
The method could be extended to look for non-repeating patterns across patients. 
The CPAM had good performance for both simple and complex plans where all 
components of the plan recur for each cycle.  However, the CPAM had more difficulty 
for those cases where some component of the plan is missing in one or more cycles. For 
example, one of the valid chemotherapy plans involves a combination of the drugs 
“Irinotecan” and “Leucovorin" given every two weeks. In some cases however, the 
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patient received only “Irinotecan” for some events, thus breaking the pattern of 
combination drugs. For those patients the method produced a plan sequence consisting of 
two distinct plans, one each corresponding to “IRIN+LEUC” and “IRIN” (represented by 
respective abbreviated drug names), instead of the actual plan “IRIN{+LEUC}” (the 
braces around the LEUC being indicative of the fact that the last component of the plan 
was missed during the trailing cycles). This happens because, 1) the event corresponding 
to IRIN by itself repeats, and 2) IRIN by itself is a valid chemotherapy plan. 
Finally, the CPAM is limited in its ability to classify distinct plans with the same 
drugs but different cycle frequency. A good example involves the drug PACLITAXEL 
where there are two distinct plans that use the single drug, one that is given at the 
frequency of 7 days and the other at a frequency of 14 days. This is evident in figure 5.2, 
which shows a bimodal distribution of cycle frequency (periodicity). These two distinct 
plans could be easily resolved by considering the cycle frequency as part of the plan 
abstraction method. 
6.2.3. Lack of query tool and incremental data analysis 
The CPAM does not offer any GUI based query mechanism to efficiently conduct 
either patient level or cohort level plan analysis. Data abstraction and analysis is done 
using the SQL through standard query tools and requires adequate technical skills.  
Development of a query tool would enhance the utility of the method for researchers. 
Finally, this initial implementation of the CPAM performs a one-time retrospective 
data analysis. The method does not allow for continuous updates of the plans as new data 
emerges in time. The technical implementation of the method would need to be extended 
to accommodate this requirement. 
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6.3. Clinical contributions 
In addition to being a simple data-driven approach to temporal abstraction the 
CPAM has already demonstrated applications for clinical research including 
identification of cohorts by treatment plan and identification of practice patterns at our 
institution.  
The CPAM was used for cohort identification to isolate lung cancer patients who 
had received two distinct chemotherapy plans as their first treatment. Using the tumor 
registry database to identify cases of lung cancer, the CPAM was able to accurately 
segregate two sub-populations, one following the chemotherapy plan “Bevacizumab + 
Carboplatin + Paclitaxel” and the other following the plan “Carboplatin + Paclitaxel”. 
The two cohorts are being evaluated for the presence of genetic variations that may 
predict response to Bevacizumab. Prior to the development of the CPAM, it would have 
taken a significant amount of time, effort and cost to isolate the two patient cohorts 
through manual chart review of hundreds of lung cancer patients. 
The CPAM has been used to evaluate the practice patterns for breast cancer patients 
at the VICC. The across plan analysis provided listing of the most frequently 
administered plans for this population (Table 5.3 and Appendix A). This demonstrates the 
trends in chemotherapy prescribing patterns at our institution over the last 5 years. The 
list has been used for operational purposes to help prioritize the creation of the order sets 
for the new chemotherapy CPOE system at the VICC. It could also be used to analyze 
resource utilization by the pharmacy department to help prioritize purchasing 
requirements and other resource planning tasks.  
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The within plan analyses facilitated important information regarding the provider 
practice patterns, patient tolerance to the treatment, and tumor response to the treatment. 
Figures 5.1 and 5.2 show the distribution of the periodicity, number of cycles and 
sequence of therapy for the two most frequently administered breast cancer plans. The 
analysis shows the degree of concordance with the established standard of care for these 
protocols. In particular, the most commonly prescribed plan “Cyclophosphamide + 
Doxorubicin”, is typically administered every 14 days for 4 cycles. The data for 198 
patients shows an average cycle frequency of 15.8 days with an average of 3.8 cycles. 
This means that most patients were able to tolerate the treatment on the standard 
schedule. This has important implications for both, assessing the quality of care and 
identifying therapies where toxicities often require deviation from the standard schedule. 
A within plan analysis can also be used to estimate the time to disease progression 
(TTP) for a given therapy. TTP is typically measured from the date of the first treatment 
until the date the tumor is documented to progress, typically measured by imaging 
studies. The CPAM documents the duration of the treatment, which could be a surrogate 
for TTP for certain clinical settings. Figure 6.1 shows the distribution plot of the number 
of cycles for the “Fulvestrant” plan, a medication given only in the metastatic setting for 
breast cancer.  Fulvestrant is typically given every 4 weeks, such that the number of 
cycles corresponds to the number of months the treatment was given. The distribution 
plot for this plan shows a median number of cycles to be about 4 and the average number 
of cycles is 6.4. These numbers have close correspondence to the median TTP of 5.5 
months observed by Robertson et al. in a prospective analysis of two multicenter trial of 
Fulvestrant versus Anastrozole(44). While the patient sample size of this multicenter 
 study was much larger (n=428), and that of the VICC is much small
proximity of the TTP value shows the importance of the cohort analysis that can be done 
with the output produced by the CPAM. 
 
Figure 6.1. # of Cycles distribution for the treatment plan of Fulvestrant
Violin-plot of the distribution for number of cycles for 
chemotherapy treatment plan of Fulvestrant
 
Given that the chemotherapy plans can be readily 
medication events, the 
chemotherapy treatments. 
save laborious effort, significant amount of time to collect and analyze data for discrete 
drug events, and considerable amount of cost to
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Using the CPAM to produce chemotherapy treatment plans can 
 the investigators of such studies.
er (n=55), the 
 
a set of 
of 
  
73 
 
6.4. Clinical limitations 
We have demonstrated some utility of the CPAM for clinical research however, it 
does have some limitations. First, the method is currently restricted to medications that 
were administered at the institution’s infusion center. In order to provide a complete 
treatment history, the data sources and the CPAM would need to be extended to include 
oral and intravenous medications not administered at the VUMC. Second, the current 
implementation of CPAM does not take into account any dose variations, and it also does 
not indicate at the output if there were any dose variations. The method only recognizes a 
complete absence of an administration event. Such enhancements would be valuable both 
clinically and for research. 
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CHAPTER 7  
CONCLUSION AND FUTURE DIRECTIONS 
 
7.1. Conclusions 
The CPAM is a temporal reasoning method that accurately abstracts a sequence of 
chemotherapy plans at the patient level. The major advantage of the CPAM is its simple 
data-driven approach to plan abstraction that does not require maintenance of an external 
knowledge base of plans. The utility of the CPAM is further demonstrated through 
several cohort plan analyses that provide information on provider practice patterns, plan 
adherence to standard of care, patient toxicity, and tumor response to treatment. 
7.2. Future directions 
The CPAM could be further extended in several dimensions for both patient care and 
clinical research. 
7.2.1. Implementation in clinical care systems for patient care 
The CPAM could prove to be a useful tool in a clinical setting if incorporated into 
EHR systems or in the chemotherapy flow sheets. The tool can produce the abstract form 
of chemotherapy plans instead of the simple chronology of discrete drug events. In a 
clinical system, the CPAM could decrease the time spent by a clinician to perform 
chemotherapy plan abstraction. A system could also be developed that utilizes the CPAM 
to help create treatment summaries in the form suggested by ASCO(3).  
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7.2.2. Extensions for clinical research 
Within oncology, the CPAM could be extended in a number of dimensions to further 
facilitate clinical research. First, the method could be extended to take medication event 
input from additional data sources including inpatient and outpatient CPOE, nursing 
administration records, and clinical notes. It could also be extended to continuously 
update plans as new drug events occur over time. The addition of a GUI for plan query 
would also facilitate research utilization of the important abstracted data. 
In order to facilitate comparative effectiveness research, additional patient data 
would need to be integrated with the abstracted treatment plans produced by the CPAM. 
Preliminary work towards this end has been already demonstrated by the use of diagnosis 
and histology data from the tumor registry database. Additional tumor registry and 
clinical data features such as demographics, cancer stage, tumor biomarkers and vital 
status would also need to be integrated to facilitate CER. In addition, the cost of 
treatments could be included to perform comparative cost analysis. 
7.2.3. Application to other clinical domains 
Many chronic diseases such as diabetes, hypertension, cardiovascular disease, and 
HIV, require ongoing management and assessment by the special providers. The 
treatments of such diseases are continuous and prolonged, and involve multiple groups of 
treatments over time. On these premises, it should be possible to extend use of the CPAM 
to infer treatment plans for such diseases too. Given the fact that the medication 
administration for most of these diseases is on an outpatient basis, and the medication 
administration events are relatively unreliable, it would require incorporation of some 
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stochastic techniques to establish the authenticity of the medication events to accurately 
abstract corresponding plans. 
Healthcare providers routinely perform the task of reviewing a patient’s medication 
history, which can be quite laborious. Given that all the raw data required for such 
summaries are already available in many EHR systems, incorporation of abstraction tools 
like CPAM could significantly improve provider workflow. Similarly, secondary use of 
EHR data does not have to involve manual reviews and creation of ad-hoc processes. 
Researchers’ resources are better spent at thinking in terms of abstract ideas rather than 
mundane task of sifting through distinct low-level data items. CPAM-like tools could 
provide such abstract level output for analysis of EHR data. The CPAM has great 
potential to assist both the clinical care and clinical research. 
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APPENDIX – A 
 
BREAST CANCER CHEMOTHERAPY PLANS 
 
Table A–1. List of chemotherapy plans for breast cancer patient cohort, in descending order of 
frequency of administration. 
  Counts Periodicity Dose Count 
PLAN 
Plan 
Cnt. 
Distinct 
Pt. 
Cnt. Avg. 
std. 
dev. Min. Max. Avg. 
Std. 
dev. Min. Max. 
CYCL+DOXO 201 198 15.8 3.1 7.0 28.0 3.6 0.9 1.0 6.0 
PACL 138 138 10.6 4.7 6.4 29.4 7.1 4.3 1.0 16.0 
TRAS 72 61 22.1 8.6 7.8 63.0 9.0 11.1 1.0 64.0 
FULV 55 55 27.3 16.6 13.0 107.5 6.4 8.5 1.0 53.0 
CYCL+DOCE 48 46 21.7 1.8 20.0 29.7 3.7 1.0 1.0 6.0 
VINO 47 47 14.6 12.6 6.0 67.0 6.1 8.1 1.0 47.0 
GOSE 44 42 42.6 23.2 24.0 119.0 7.7 6.6 1.0 31.0 
PACL+TRAS, TRAS 36 36 68.2 65.9 21.0 178.0 1.2 0.5 1.0 3.0 
BEVA 33 32 17.2 3.5 13.8 26.3 10.7 16.5 1.0 92.0 
DOXO 32 32 14.0 9.5 7.0 43.0 4.4 8.7 1.0 51.0 
DOCE 31 31 14.6 4.5 7.0 25.2 3.9 3.7 1.0 21.0 
GEMC 30 30 12.9 5.3 7.0 29.8 4.3 5.1 1.0 28.0 
BEVA+PACL, PACL 27 25 18.8 5.4 14.0 34.0 5.0 6.4 1.0 33.0 
CARB+GEMC 23 23 14.2 3.4 7.0 21.0 5.4 3.7 1.0 15.0 
CISP+PACL 16 16 10.9 2.0 7.0 14.5 8.6 7.8 1.0 35.0 
TRAS+VINO, VINO 16 14 30.3 14.2 21.0 63.0 3.9 2.8 1.0 10.0 
BEVA+CYCL+DOXO 14 14 14.1 0.7 13.0 15.7 3.4 1.2 1.0 4.0 
CARB+DOCE+TRAS, TRAS 13 13 28.0 0.0 28.0 28.0 1.2 0.6 1.0 3.0 
CISP+PACL, PACL 12 11 85.3 68.2 14.0 150.0 1.3 0.5 1.0 2.0 
PACL, BEVA+PACL 10 10 30.0 11.4 14.0 49.0 5.6 6.7 1.0 24.0 
CISP, CISP+PACL 9 9         1.0 0.0 1.0 1.0 
PACL+TRAS 9 9 19.3 26.1 7.0 77.0 5.1 4.5 1.0 12.0 
NAB- 9 9 12.9 7.5 8.8 27.7 4.4 3.4 1.0 9.0 
CYCL+FLUO+METH 8 8 22.2 1.8 21.0 25.5 3.6 2.2 1.0 6.0 
BEVA+PACL, BEVA 7 7 218.0 0.0 218.0 218.0 1.3 0.8 1.0 3.0 
PACL+TRAS, PACL 7 7 17.5 4.9 14.0 21.0 1.9 1.1 1.0 4.0 
TRAS, PACL+TRAS 7 7 119.0 120.4 49.0 258.0 3.6 3.1 1.0 8.0 
CISP+PACL, CISP 6 6 37.0 0.0 37.0 37.0 1.3 0.8 1.0 3.0 
TRAS+VINO 6 6 14.0 0.0 14.0 14.0 1.2 0.4 1.0 2.0 
CARB 5 5 8.4 1.3 7.0 9.3 2.4 1.5 1.0 4.0 
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CARB+DOCE+TRAS 5 5 21.1 0.1 21.0 21.2 2.2 2.2 1.0 6.0 
CARB+GEMC, GEMC 5 5 46.3 25.6 21.0 82.0 3.6 4.2 1.0 11.0 
TRAS, CARB+DOCE+TRAS 5 5         1.8 0.4 1.0 2.0 
IXAB 5 5 7.9 2.4 6.3 11.4 12.6 12.5 1.0 33.0 
BEVA+DOCE 4 4 20.8 5.7 14.0 28.0 3.8 2.1 2.0 6.0 
CARB+DOCE 4 4 8.4 0.0 8.4 8.4 2.3 2.5 1.0 6.0 
BSI-+CARB+GEMC, BSI- 4 4 10.7 9.0 5.0 21.0 6.3 5.1 1.0 12.0 
CARB+PACL 4 4 10.2 6.7 6.0 20.3 5.5 5.7 2.0 14.0 
DOCE+TRAS 4 4 7.9 1.3 7.0 8.8 2.3 1.9 1.0 5.0 
RITU 4 4 7.5 1.0 7.0 9.0 4.0 0.0 4.0 4.0 
FULV+GOSE 4 4 30.5 3.5 28.0 33.0 2.0 1.4 1.0 4.0 
CYCL+DOXO, TRAS 4 4         1.0 0.0 1.0 1.0 
BEVA+PACL+TRAS 4 3 14.0 0.0 14.0 14.0 2.0 2.0 1.0 5.0 
BEVA+PACL 4 4         1.0 0.0 1.0 1.0 
BEVA+GEMC, GEMC 3 3 24.5 4.9 21.0 28.0 1.7 0.6 1.0 2.0 
BEVA+PACL+TRAS, 
PACL+TRAS 3 2 28.0 0.0 28.0 28.0 1.3 0.6 1.0 2.0 
VINO, TRAS+VINO 3 3 574.0 0.0 574.0 574.0 1.3 0.6 1.0 2.0 
TRAS, FULV 3 1 23.3 4.0 21.0 28.0 3.3 0.6 3.0 4.0 
GOSE+TRAS, TRAS 3 3 35.5 9.2 29.0 42.0 2.3 1.2 1.0 3.0 
CYTA 3 3 13.0 0.0 13.0 13.0 1.3 0.6 1.0 2.0 
CARB+PACL+TRAS 3 2 7.0 0.0 7.0 7.0 1.7 0.6 1.0 2.0 
BEVA+CARB+GEMC 2 1 21.0 0.0 21.0 21.0 1.5 0.7 1.0 2.0 
BEVA+GEMC 2 2 14.0 0.0 14.0 14.0 1.5 0.7 1.0 2.0 
BSI-+CARB, BSI- 2 2 18.0 4.2 15.0 21.0 3.5 2.1 2.0 5.0 
FLUO 2 2         1.0 0.0 1.0 1.0 
FULV+GOSE, FULV 2 2 28.0 0.0 28.0 28.0 1.5 0.7 1.0 2.0 
GEMC, GEMC+TRAS 2 2 20.0 0.0 20.0 20.0 2.0 1.4 1.0 3.0 
VINO, TRAS 2 2 22.0 0.0 22.0 22.0 1.5 0.7 1.0 2.0 
VINO, BEVA+VINO 2 2 24.0 5.7 20.0 28.0 3.5 2.1 2.0 5.0 
TRAS, PACL 2 2 133.0 0.0 133.0 133.0 2.0 1.4 1.0 3.0 
TRAS, CARB+PACL 2 2 20.0 0.0 20.0 20.0 1.5 0.7 1.0 2.0 
T-DM 2 2 23.0 0.3 22.8 23.2 21.0 15.6 10.0 32.0 
PACL, CARB+PACL 2 2 21.0 0.0 21.0 21.0 2.0 1.4 1.0 3.0 
GEMC+TRAS 2 2 14.0 0.0 14.0 14.0 1.5 0.7 1.0 2.0 
FLUO+METH 2 2 7.0 0.0 7.0 7.0 1.5 0.7 1.0 2.0 
DOCE+TRAS, TRAS 2 2 75.0 0.0 75.0 75.0 4.5 4.9 1.0 8.0 
CISP+DOXO 2 2 10.7 0.0 10.7 10.7 2.5 2.1 1.0 4.0 
BEVA+VINO 2 2         1.0 0.0 1.0 1.0 
BEVA+DOCE, DOCE 2 2 14.0 0.0 14.0 14.0 3.5 3.5 1.0 6.0 
ALDE 1 1 1.0 0.0 1.0 1.0 4.0 0.0 4.0 4.0 
CARB+PACL, 1 1 14.0 0.0 14.0 14.0 3.0 0.0 3.0 3.0 
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BEVA+CARB+PACL 
DOCE+NAB- 1 1         1.0 0.0 1.0 1.0 
DOCE+GEMC 1 1         1.0 0.0 1.0 1.0 
DOCE+DOXO 1 1         1.0 0.0 1.0 1.0 
DENO 1 1 39.0 0.0 39.0 39.0 3.0 0.0 3.0 3.0 
CYCL+FLUO 1 1 19.0 0.0 19.0 19.0 2.0 0.0 2.0 2.0 
CYCL+EPIR 1 1         1.0 0.0 1.0 1.0 
CYCL+DOXO+RITU+VINC 1 1 21.0 0.0 21.0 21.0 3.0 0.0 3.0 3.0 
CYCL 1 1         1.0 0.0 1.0 1.0 
CISP+PACL, PACL, CISP 1 1         1.0 0.0 1.0 1.0 
CISP+ETOP, ETOP 1 1 28.0 0.0 28.0 28.0 4.0 0.0 4.0 4.0 
CISP 1 1 12.3 0.0 12.3 12.3 8.0 0.0 8.0 8.0 
CARB+PACL, CARB 1 1         1.0 0.0 1.0 1.0 
VINB 1 1 9.0 0.0 9.0 9.0 2.0 0.0 2.0 2.0 
TRAS, GEMC+TRAS 1 1 61.0 0.0 61.0 61.0 2.0 0.0 2.0 2.0 
TOPO 1 1 6.7 0.0 6.7 6.7 16.0 0.0 16.0 16.0 
NAB-+TRAS 1 1         1.0 0.0 1.0 1.0 
MM-1 1 1 7.0 0.0 7.0 7.0 3.0 0.0 3.0 3.0 
MITO 1 1 26.0 0.0 26.0 26.0 2.0 0.0 2.0 2.0 
METH 1 1         1.0 0.0 1.0 1.0 
IXAB+TRAS 1 1         1.0 0.0 1.0 1.0 
IRIN 1 1 28.0 0.0 28.0 28.0 2.0 0.0 2.0 2.0 
GEMC, DOCE 1 1         1.0 0.0 1.0 1.0 
GEMC+TRAS, GEMC 1 1 22.0 0.0 22.0 22.0 5.0 0.0 5.0 5.0 
FULV, TRAS 1 1 14.0 0.0 14.0 14.0 2.0 0.0 2.0 2.0 
FULV, DENO 1 1 65.0 0.0 65.0 65.0 2.0 0.0 2.0 2.0 
FULV+TRAS 1 1         1.0 0.0 1.0 1.0 
ERIB 1 1 14.0 0.0 14.0 14.0 4.0 0.0 4.0 4.0 
EPIR 1 1 7.0 0.0 7.0 7.0 2.0 0.0 2.0 2.0 
DOXO+IFOS 1 1 8.0 0.0 8.0 8.0 14.0 0.0 14.0 14.0 
CARB+DOCE, CARB 1 1 35.0 0.0 35.0 35.0 2.0 0.0 2.0 2.0 
CARB+DOCE+TRAS, TRAS, 
CARB+DOCE 1 1 50.0 0.0 50.0 50.0 2.0 0.0 2.0 2.0 
BORT 1 1 8.2 0.0 8.2 8.2 13.0 0.0 13.0 13.0 
BEVA+TRAS 1 1 21.0 0.0 21.0 21.0 16.0 0.0 16.0 16.0 
BEVA+NAB- 1 1         1.0 0.0 1.0 1.0 
BEVA+PACL, PACL, BEVA 1 1 28.0 0.0 28.0 28.0 2.0 0.0 2.0 2.0 
BEVA+CARB+GEMC, 
BEVA+GEMC 1 1 80.0 0.0 80.0 80.0 2.0 0.0 2.0 2.0 
 
 
